<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006162.pub2" GROUP_ID="ENDOC" ID="073906051611144632" MERGED_FROM="" MODIFIED="2008-11-03 12:14:31 +0100" MODIFIED_BY="Gudrun Paletta" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="4.0">
<COVER_SHEET MODIFIED="2008-11-03 12:14:31 +0100" MODIFIED_BY="Gudrun Paletta">
<TITLE>Rimonabant for overweight or obesity</TITLE>
<CONTACT MODIFIED="2008-11-03 12:14:31 +0100" MODIFIED_BY="Gudrun Paletta"><PERSON ID="C30FDE5A82E26AA2016B340A33BEA8EB" ROLE="AUTHOR"><FIRST_NAME>Cintia</FIRST_NAME><LAST_NAME>Curioni</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>c_curioni@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Instituto de Medicina Social</DEPARTMENT><ORGANISATION>Universidade do Estado do Rio de Janeiro</ORGANISATION><ADDRESS_1>Rua São Francisco Xavier, 524 / 7º andar / bloco D - Maracanã</ADDRESS_1><CITY>Rio de Janeiro</CITY><ZIP>20559-900</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 21 2548-3616</PHONE_1><FAX_1>+55 21 2548-3616</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-11-03 12:14:31 +0100" MODIFIED_BY="Gudrun Paletta"><PERSON ID="C30FDE5A82E26AA2016B340A33BEA8EB" ROLE="AUTHOR"><FIRST_NAME>Cintia</FIRST_NAME><LAST_NAME>Curioni</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>c_curioni@uol.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Instituto de Medicina Social</DEPARTMENT><ORGANISATION>Universidade do Estado do Rio de Janeiro</ORGANISATION><ADDRESS_1>Rua São Francisco Xavier, 524 / 7º andar / bloco D - Maracanã</ADDRESS_1><CITY>Rio de Janeiro</CITY><ZIP>20559-900</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 21 2548-3616</PHONE_1><FAX_1>+55 21 2548-3616</FAX_1></ADDRESS></PERSON><PERSON ID="C32530BC82E26AA2016B340AC66ECFA8" ROLE="AUTHOR"><FIRST_NAME>Charles</FIRST_NAME><LAST_NAME>André</LAST_NAME><POSITION>Adjunct Professor</POSITION><EMAIL_1>andrecmd@unisys.com.br</EMAIL_1><ADDRESS><DEPARTMENT>Neurology</DEPARTMENT><ORGANISATION>Federal University of Rio de Janeiro</ORGANISATION><ADDRESS_1>Serviço de Neurologia, Hospital Universario Clementino Fraga Filho,</ADDRESS_1><ADDRESS_2>Av Brigadeiro Trompowsky, s/no  sala 10E36</ADDRESS_2><CITY>Rio de Janeiro</CITY><ZIP>22441-090</ZIP><COUNTRY CODE="BR">Brazil</COUNTRY><PHONE_1>+55 021 25902738</PHONE_1><FAX_1>+55 021 25902738</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-11-03 11:56:26 +0100" MODIFIED_BY="Gudrun Paletta">
<UP_TO_DATE>
<DATE DAY="30" MONTH="6" YEAR="2006"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="30" MONTH="6" YEAR="2006"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="31" MONTH="8" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="2006"/>
<LAST_CITATION_ISSUE ISSUE="4" YEAR="2006"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="4" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2008-10-04 16:11:18 +0200" MODIFIED_BY="[Empty name]"/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Instituto de Medicina Social - UERJ</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Universidade Federal do Rio de Janeiro</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>FAPERJ</NAME>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-11-03 12:11:54 +0100" MODIFIED_BY="Gudrun Paletta">
<SUMMARY MODIFIED="2008-11-03 11:56:59 +0100" MODIFIED_BY="Gudrun Paletta">
<TITLE MODIFIED="2008-10-04 16:16:12 +0200" MODIFIED_BY="[Empty name]">Rimonabant for overweight or obesity</TITLE>
<SUMMARY_BODY MODIFIED="2008-11-03 11:56:59 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Rimonabant is the first drug of a new class of medications that seems to reduce body weight and improve risk factors for diseases of the blood vessels and heart in people who are overweight or obese. We found four studies which evaluated weight loss, occurrence of disorders and adverse effects of treatment. The four studies involved 6625 people comparing rimonabant 20 mg with rimonabant 5 mg and placebo, in combination with a hypocaloric diet after one or two years of treatment. Greater weight loss and improvement in risk factors were seen after 20 mg of rimonabant. These results have to be interpreted with caution though, due to high discontinuation rates of study participants and the overall low quality of the included studies.<BR/>We conclude that: 1. average weight loss with rimonabant appears modest, and 2. more rigorous studies examining the efficacy and safety of rimonabant are required to fully evaluate the benefit risk ratio of this new drug.<BR/>In Europe, rimonabant is contraindicated for patients with severe depression and/or patients who are treated with antidepressive medications. Rimonabant is furthermore not recommended for patients with other untreated psychiatric conditions.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2008-11-03 11:55:45 +0100" MODIFIED_BY="Gudrun Paletta">
<ABS_BACKGROUND>
<P>Worldwide, the prevalence of obesity and overweight in industrialized countries and in a substantial number of developing countries is increasing at an alarming rate. Rimonabant is a selective cannabinoid-1 receptor antagonist that has been investigated for its efficacy in reducing body weight and associated risk factors in obese people. Phase III trials are now under way to test the use of rimonabant for long-term weight-loss. Given the prevalence of overweight and obesity, it is important to establish the efficacy and safety of rimonabant.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To assess the effects of rimonabant in overweight and obese people.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2008-10-04 17:09:31 +0200" MODIFIED_BY="[Empty name]">
<P>MEDLINE, EMBASE, <I>The Cochrane Library</I>, LILACS, databases of ongoing trials and reference lists were used to identify relevant trials. </P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>Randomised controlled trials comparing rimonabant with placebo or other weight loss interventions in overweight or obese adults.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two reviewers independently assessed all potentially relevant citations for inclusion and methodological quality. The primary outcome measures were weight loss change, morbidity and adverse effects occurrence.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Four studies evaluating rimonabant 20 mg versus rimonabant 5 mg versus placebo in addition to a hypocaloric diet lasting at least one year were included. Compared with placebo, rimonabant 20 mg produced a 4.9 kg greater reduction in body weight in trials with one-year results. Improvements in waist circumference, high-density lipoprotein cholesterol, triglyceride levels and systolic and diastolic blood pressure were also seen. However, the results with rimonabant 5 mg demonstrated a weight reduction which was only 1.3 kg greater when compared with placebo. No clinically relevant effects on plasma lipids and blood pressure were found. Rimonabant 20 mg caused significant more adverse effects both of general and serious nature, especially of nervous system, psychiatric or gastro-intestinal origin. Attrition rates were approximately 40% at the end of one year.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2008-11-03 11:55:45 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The use of rimonabant after one year produces modest weight loss of approximately 5%. Even modest amounts of weight loss may be potentially beneficial. The observed results should be interpreted with some caution, though, since the evaluated studies presented some deficiencies in methodological quality. Studies with longer follow-ups after the end of treatment and of more rigorous quality should be done before definitive recommendations can be made regarding the role of this new medication in the management of overweight or obese patients.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-11-03 12:11:54 +0100" MODIFIED_BY="Gudrun Paletta">
<BACKGROUND MODIFIED="2008-11-03 12:11:54 +0100" MODIFIED_BY="Gudrun Paletta">
<CONDITION MODIFIED="2008-11-03 12:11:26 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Worldwide, the prevalence of obesity and overweight in industrialized countries and in a substantial number of developing countries is increasing at an alarming rate (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>). This problem is associated with a large variety of health consequences representing an enormous burden on health care systems and, most importantly, the quality of life of the affected individuals might be substantially lowered.<BR/>Obesity refers to an excess of body fat or adiposity. Body mass index (BMI; in kg/m<SUP>2</SUP>) is widely recognized as a weight-for-height index that has a high correlation with adiposity. In clinical terms, a BMI of 25-29 kg/m<SUP>2</SUP> is classified as overweight and a higher BMI (greater than 30 kg/m<SUP>2</SUP>) reflects obesity (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>).<BR/>Overweight and obesity are associated with a large variety of health consequences, including hypertension (<LINK REF="REF-Brown-2000" TYPE="REFERENCE">Brown 2000</LINK>; <LINK REF="REF-Dyer-1989" TYPE="REFERENCE">Dyer 1989</LINK>), type 2 diabetes mellitus (<LINK REF="REF-Medalie-1974" TYPE="REFERENCE">Medalie 1974</LINK>; <LINK REF="REF-Ohlson-1985" TYPE="REFERENCE">Ohlson 1985</LINK>), heart diseases (<LINK REF="REF-NIHCD-1985" TYPE="REFERENCE">NIHCD 1985</LINK>; <LINK REF="REF-Willett-1995" TYPE="REFERENCE">Willett 1995</LINK>), stroke (<LINK REF="REF-Rexrode-1997" TYPE="REFERENCE">Rexrode 1997</LINK>; <LINK REF="REF-Walker-1996" TYPE="REFERENCE">Walker 1996</LINK>), osteoarthritis (<LINK REF="REF-Cicuttini-1996" TYPE="REFERENCE">Cicuttini 1996</LINK>; <LINK REF="REF-Hart-1993" TYPE="REFERENCE">Hart 1993</LINK>), sleep apnoea and respiratory difficulties (<LINK REF="REF-Chua-1994" TYPE="REFERENCE">Chua 1994</LINK>) and also several common cancers (<LINK REF="REF-Bergstrom-2001" TYPE="REFERENCE">Bergstrom 2001</LINK>; <LINK REF="REF-Chu-1991" TYPE="REFERENCE">Chu 1991</LINK>; <LINK REF="REF-Schottenfeld-1996" TYPE="REFERENCE">Schottenfeld 1996</LINK>).<BR/>The presence of excess fat in the abdomen out of proportion to total body fat is an independent predictor of type 2 diabetes, dyslipidaemia, hypertension and cardiovascular disease (<LINK REF="REF-NHLBI-1998" TYPE="REFERENCE">NHLBI 1998</LINK>). Waist circumference and waist-to-hip circumference ratios (WHR) are simple and convenient for epidemiological studies and provide a useful estimation of the proportion of abdominal or upper-body fat (<LINK REF="REF-Bj_x00f6_rntorp-1984" TYPE="REFERENCE">Björntorp 1984</LINK>; <LINK REF="REF-Bj_x00f6_rntorp-1985" TYPE="REFERENCE">Björntorp 1985</LINK>; <LINK REF="REF-Kissebah-1985" TYPE="REFERENCE">Kissebah 1985</LINK>). Several studies have investigated the correlation of abdominal fat and increased mortality and risk for disorders such as diabetes, hyperlipidaemia, hypertension and cardiovascular diseases (<LINK REF="REF-Donahue-1987" TYPE="REFERENCE">Donahue 1987</LINK>; <LINK REF="REF-Ducimetiere-1986" TYPE="REFERENCE">Ducimetiere 1986</LINK>; <LINK REF="REF-Lapidus-1984" TYPE="REFERENCE">Lapidus 1984</LINK>; <LINK REF="REF-Larsson-1984" TYPE="REFERENCE">Larsson 1984</LINK>; <LINK REF="REF-Ohlson-1985" TYPE="REFERENCE">Ohlson 1985</LINK>; <LINK REF="REF-Stokes-1985" TYPE="REFERENCE">Stokes 1985</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2008-10-04 16:18:27 +0200" MODIFIED_BY="[Empty name]">
<P>Obesity is seen as a disease, which requires treatment. Treatment means, first of all, weight reduction. The general goals of weight loss and management are:<BR/>(1) to reduce body weight; and<BR/>(2) to maintain a lower body weight over the long term; or<BR/>(3) at a minimum, to prevent further weight gain.<BR/>There is strong evidence that weight loss (5% to 15% of the body weight) in obese individuals reduces risk factors associated with obesity (<LINK REF="REF-NHLBI-1998" TYPE="REFERENCE">NHLBI 1998</LINK>).</P>
<P>Traditional methods to promote weight loss focus on reducing energy intake through low-calorie or low-fat diets, increasing energy expenditure by increase in physical activity, and behavioural modification. The inclusion of exercise in a weight reduction program is supposed to make the weight loss easier, compared with food restriction alone. However, the effectiveness of these weight reduction methods is limited, with an overall pattern of moderate weight loss followed by gradual weight regain (<LINK REF="REF-Curioni-2005" TYPE="REFERENCE">Curioni 2005</LINK>).<BR/>Numerous other weight loss interventions are available including pharmacotherapy, surgery to reduce food consumption and alternative therapies. Surgical procedures have greater long-term success rates but are currently indicated for the very obese only (BMI greater than 40 kg/m<SUP>2</SUP> or BMI 35 to 40 kg/m<SUP>2</SUP> together with an obesity-related disorder). Operative mortality rates are reported to average below one percent, but long-term complications such as malabsorption syndromes may occur (<LINK REF="REF-Greenway-1996" TYPE="REFERENCE">Greenway 1996</LINK>).<BR/>Pharmacotherapy should be considered in overweight and obese patients with a BMI greater than 27 kg/m<SUP>2</SUP>, particularly in the presence of comorbidities or an increased waist circumference, when conservative measures such as behaviour therapy, diet and exercise have not resulted in the desired weight loss (<LINK REF="REF-NHLBI-1998" TYPE="REFERENCE">NHLBI 1998</LINK>). Drugs should always be used in conjunction with non-pharmacological therapy, though.</P>
<P>Approved anti-obesity medications can be divided into two broad categories:<BR/>(1) Inhibitors of intestinal fat absorption, where the only agent currently available compound in this class is orlistat, a drug that inhibits pancreatic and other lipases. Side effects are related to malabsorption of fat within the gastrointestinal tract and include steatorhea, bloating, and oily discharge. Fecal incontinence and malabsorption of fat-soluble vitamins, such as vitamin A, D, E, and K, have also been reported (<LINK REF="REF-McNeely-1998" TYPE="REFERENCE">McNeely 1998</LINK>).<BR/>(2) Drugs that act to suppress appetite. An example of this category includes sibutramine, which inhibits re-uptake of serotonin and norepinephrine. The most common adverse effects are related to increased adrenergic activity and include dry mouth, headache, insomnia, and constipation. Sibutramine may also cause increases in blood pressure and heart rate (<LINK REF="REF-Luque-1999" TYPE="REFERENCE">Luque 1999</LINK>).<BR/>Orlistat and sibutramine are the only medications approved for long-term use.</P>
<P>A number of anti-obesity drugs are currently undergoing clinical development. These include:<BR/>(1) Centrally-acting drugs, such as the noradrenergic and dopaminergic re-uptake inhibitor rodafaxine, the endocannabinoid antagonist rimonabant, the selective serotonin 5-HT<SUB>2C</SUB> agonist APD-356, and oleoyl-estrone;<BR/>(2) Drugs that target peripheral episodic satiety signals, such as glucagon-like peptide-1, peptide YY and amylin;<BR/>(3) Drugs that block fat absorption, such as the novel lipase inhibitors cetilistat and GT-389255; and<BR/>(4) A human growth hormone fragment (AOD-9604) that increases adipose tissue breakdown (<LINK REF="REF-Halford-2006" TYPE="REFERENCE">Halford 2006</LINK> ).<BR/>Most of these investigational drugs are in the early or mid-stages of development. Rimonabant is the only drug in the late-stage of investigations.</P>
</INTERVENTION>
<THEORY MODIFIED="2008-11-03 12:11:54 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Rimonabant is a selective cannabinoid-1 receptor antagonist that has been investigated for its efficacy in reducing body weight and associated risk factors in obese people (<LINK REF="REF-Bonner-2005" TYPE="REFERENCE">Bonner 2005</LINK>). The cannabinoid-1 receptor plays a role in the regulation of appetite and body weight. The endocannabinoid system (EC) consists of cannabinoids receptors (CB<SUB>1</SUB> receptors) and endocannabinoids, as well as enzymes catalysing their biosynthesis and degradation (<LINK REF="REF-Di-Marzo-2005" TYPE="REFERENCE">Di Marzo 2005</LINK>). CB<SUB>1</SUB> receptors are expressed predominantly in several areas of the brain and in peripheral organs, including the autonomic nervous system, liver, muscle, gastrointestinal tract, and adipose tissue (<LINK REF="REF-Di-Marzo-2004" TYPE="REFERENCE">Di Marzo 2004</LINK>). Pharmacological stimulation of CB<SUB>1</SUB> receptors by systemic administration of plant or endogenous cannabinoids stimulates eating, even in satiated animals (<LINK REF="REF-Colombo-1998" TYPE="REFERENCE">Colombo 1998</LINK>; <LINK REF="REF-Rowland-2001" TYPE="REFERENCE">Rowland 2001</LINK>; <LINK REF="REF-Simiand-1998" TYPE="REFERENCE">Simiand 1998</LINK>).<BR/>The administration of the first selective CB<SUB>1</SUB> antagonist (rimonabant) attenuated agonists' stimulatory effects on food intake and strongly reduced both the consumption of palatable food (such as sweet food) and the intake of normal food by animals deprived of food (<LINK REF="REF-Rinaldi_x002d_Carmona-2004" TYPE="REFERENCE">Rinaldi-Carmona 2004</LINK>; <LINK REF="REF-Werner-2003" TYPE="REFERENCE">Werner 2003</LINK>).<BR/>The EC system may regulate food intake by modulating actions or expressions of many anorectic and orexigenic mediators in the brain, particularly hypothalamic peptides such as corticotrophin-releasing hormone (CRH) and melanin-concentrating hormone (MCH). Of particular importance are the effects of endocannabinoids on the mesolimbic system that modulates reward behaviours (such as food intake as a reward after managing stressful situations). Endocannabinoids enhance dopamine release in the nucleus accumbens, thus increase the drive to eat (<LINK REF="REF-Di-Marzo-2005" TYPE="REFERENCE">Di Marzo 2005</LINK>). Rimonabant has been shown to reduce food intake, hunger and body weight in overweight or obese men after seven days of treatment (<LINK REF="REF-Vickers-2005" TYPE="REFERENCE">Vickers 2005</LINK>).</P>
<P>Phase III trials are now under way to test the use of rimonabant for long-term weight-loss. Four clinical trials (RIO (rimonabant in obesity) <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK>, <LINK REF="STD-RIO_x002d_Europe" TYPE="STUDY">RIO-Europe</LINK>, <LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK> and <LINK REF="STD-RIO_x002d_Lipids" TYPE="STUDY">RIO-Lipids</LINK>) involving 6000 participants suggest that rimonabant 20 mg produces a placebo-subtracted weight loss of approximately five kg. No major side effects were reported; however, given the wide distribution of CB<SUB>1</SUB> receptors within the body, it is possible that the drug could affect a number of systems unrelated to eating (<LINK REF="REF-Halford-2006" TYPE="REFERENCE">Halford 2006</LINK>).<BR/>A Cochrane systematic review is being developed to analyse the efficacy of cannabinoid type 1 receptor antagonists for smoking cessation (<LINK REF="REF-Hey-2005" TYPE="REFERENCE">Hey 2005</LINK>)</P>
<SUBSECTION>
<HEADING LEVEL="3">Important adverse effects</HEADING>
<P>In Europe, rimonabant is contraindicated for patients with severe depression and/or patients who are treated with antidepressive medications. Rimonabant is furthermore not recommended for patients with other untreated psychiatric conditions.</P>
</SUBSECTION>
</THEORY>
<IMPORTANCE MODIFIED="2008-10-04 16:19:15 +0200" MODIFIED_BY="[Empty name]">
<P>There is no systematic review evaluating the efficacy and also the possible adverse effects of rimonabant in overweight or obese people. Given the prevalence of overweight and obesity, it is important to establish the possible impact of rimonabant in people suffering from these conditions.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES>
<P>To assess the effects of rimonabant in overweight and obese people.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-11-03 12:00:07 +0100" MODIFIED_BY="Gudrun Paletta">
<SELECTION_CRITERIA MODIFIED="2008-10-04 16:23:38 +0200" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>Only randomised controlled trials were considered for inclusion.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Individuals aged 18 years and older defined as overweight or obese at baseline. Criteria for defining overweight or obesity include BMI cut-off points (<LINK REF="REF-WHO-2000" TYPE="REFERENCE">WHO 2000</LINK>). Ideally, diagnostic criteria should have been described. If necessary, authors' definition of overweight or obesity were used and eventually subjected to sensitivity analysis. Studies including children, pregnant women, or patients with serious medical conditions would have been excluded.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>Interventions eligible for inclusion in the review included:<BR/>
</P>
<UL>
<LI>Rimonabant versus placebo;</LI>
<LI>Rimonabant plus other interventions such as diet or exercise versus placebo plus the same intervention;</LI>
<LI>Rimonabant versus any other pharmacological intervention;</LI>
<LI>Rimonabant versus a non-pharmacological intervention.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-04 16:23:38 +0200" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-04 16:23:26 +0200" MODIFIED_BY="[Empty name]">
<P>To be eligible for inclusion in the review, trials had to report one or more of the following outcomes:</P>
<UL>
<LI>change in weight measures (for example body weight, body mass index (BMI), waist circumference or hip/waist circumference, other anthropometric measures);</LI>
<LI>morbidity (such as cardiovascular disorders, gastrointestinal disorders, nervous system disorders, psychiatric disorders, renal and urinary disorders);</LI>
<LI>adverse effects of treatment (such as headache, nausea, anxiety, insomnia, gastrointestinal symptoms)</LI>
</UL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-04 16:23:38 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>all-cause mortality;</LI>
<LI>change in risk factors (such as blood pressure, lipid profile and HbA<SUB>1c</SUB>);</LI>
<LI>health-related quality of life (ideally using a validated instrument);</LI>
<LI>Costs.</LI>
</UL>
<SUBSECTION>
<HEADING LEVEL="5">Specific patient covariates thought to be effect modifiers</HEADING>
<UL>
<LI>compliance with the treatment;</LI>
<LI>initial overweight or obesity;</LI>
<LI>duration of the intervention.</LI>
</UL>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Timing of outcome assessment (duration of the intervention)</HEADING>
<UL>
<LI>short-term (four weeks to 24 weeks of treatment);</LI>
<LI>medium-term (more than 24 weeks to 12 months of treatment);</LI>
<LI>long-term (more than 12 months of treatment).</LI>
</UL>
</SUBSECTION>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-11-03 11:58:17 +0100" MODIFIED_BY="Gudrun Paletta">
<ELECTRONIC_SEARCHES MODIFIED="2008-11-03 11:57:54 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The following electronic databases were searched to identify relevant trials, reviews, meta-analyses, and economic analyses:<BR/>
</P>
<UL>
<LI>
<I>The Cochrane Library</I> (issue 3, 2006);</LI>
<LI>MEDLINE (up to June 2006);</LI>
<LI>EMBASE (up to June 2006);</LI>
<LI>LILACS (up to June 2006);</LI>
</UL>
<P>There were no language restrictions for either searching or trial inclusion. The search strategy using a combination of MeSH terms and text words was used for MEDLINE and was adapted to suit the other databases. For a detailed search strategy, please see under <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<SUBSECTION>
<HEADING LEVEL="4">Databases of ongoing trials</HEADING>
<UL>
<LI>Current Controlled Trials (http://www.controlled-trials.com);</LI>
<LI>National Research Register (http://www.update-software.com/National/nrr-frame.html);</LI>
<LI>National Institutes of Health (http://clinicalstudies.info.nih.gov/)</LI>
</UL>
</SUBSECTION>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-11-03 11:58:17 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Efforts were made to identify additional studies by searching the references lists of relevant trials and reviews identified.</P>
<P>Authors of relevant identified studies and other experts were contacted to obtain additional references, unpublished trials, ongoing trials and missing data not reported in the published trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-11-03 12:00:07 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY_SELECTION MODIFIED="2008-10-04 16:34:13 +0200" MODIFIED_BY="[Empty name]">
<P>Two reviewers (CC and CA) independently scanned the titles, abstracts and keywords of trials identified through the respective search strategies. The articles were evaluated for inclusion whenever there was a suggestion that they:<BR/>
</P>
<UL>
<LI>Included patients with overweight or obesity;</LI>
<LI>Compared rimonabant with placebo or another active intervention;</LI>
</UL>
<P>Articles were rejected on initial screen if both reviewers could positively determine from the title and abstract that they did not meet the inclusion criteria. All potentially relevant articles were investigated as full text. Agreement between the two reviewers was expressed using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). Eventual disagreement was resolved by discussion between the reviewers. Excluded studies and the reasons for exclusion were clearly reported in a specific table.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-11-03 12:00:07 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Two reviewers (CC and CA) independently extracted data from each study using standard data extraction forms (for details see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> and <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>; <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>; <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>; <LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>; <LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>). Differences between reviewers' extraction results were resolved by discussion. The standard data extraction forms included the following items:<BR/>
</P>
<UL>
<LI>General information: published or unpublished, title, authors, source, contact address, country, language and year of publication, duplicate publications, sponsoring, and setting;</LI>
<LI>Participants: sampling (random or convenience), exclusion criteria, total number and number in the compared groups; age; gender; initial BMI, assessment of compliance, similarity of groups at baseline (including any co-morbidity), withdrawals or losses to follow-up (reasons or description), subgroups;</LI>
<LI>Trial characteristics: design, duration, randomisation (and its method), allocation concealment (and its method), blinding (patients, people administering treatment, outcome assessors), and check of blinding;</LI>
<LI>Interventions: types, duration, description (schedule, dose, route, timing, etc.);</LI>
<LI>Outcomes: outcomes specified above, any other outcomes assessed, other events, length of follow-up, quality of reporting of outcomes;</LI>
<LI>Results: measures of effect specified above, use of intention-to-treat analysis.</LI>
</UL>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-10-04 16:34:47 +0200" MODIFIED_BY="[Empty name]">
<P>Two reviewers evaluated independently methodological quality of trials by means of individual quality component analysis (CC and CA). Inter-rater agreement was planned to be calculated using the kappa statistic (<LINK REF="REF-Cohen-1960" TYPE="REFERENCE">Cohen 1960</LINK>). Studies were not excluded only on the basis of low quality.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2008-10-04 16:35:36 +0200" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="4">Continuous data</HEADING>
<P>Continuous outcomes (for example weight loss measure by weight) were expressed, if possible, as weighted mean differences with 95% confidence intervals (CI). If results for continuous outcomes were presented on different scales, we planned to use the standardised mean differences (SMD).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Dichotomous data</HEADING>
<P>Dichotomous outcomes (for example stroke yes or no) were expressed as odds ratios (OR) or relative risks (RR) with 95% CI.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Time-to-event data</HEADING>
<P>Time-to-event outcomes (for example time until death) were expressed as hazard ratios (HR) with 95% CI.</P>
</SUBSECTION>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2008-10-04 16:37:57 +0200" MODIFIED_BY="[Empty name]">
<P>Different units of analysis (for example OR and RR) were planned to be subjected to a sensitivity analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2008-10-04 16:38:58 +0200" MODIFIED_BY="[Empty name]">
<P>When necessary, relevant missing data were sought by correspondence with the main authors of the studies. Evaluation of important numerical data such as screened, eligible and randomised patients as well as intention-to-treat and per-protocol population were carefully performed. Drop-outs, misses to follow-up and withdrawn study participants were investigated.</P>
<SUBSECTION>
<HEADING LEVEL="4">Dealing with duplicate publications</HEADING>
<P>Multiple publications were planned to be collated and assessed as one study to try maximise yield of information by simultaneous evaluation of all available data.</P>
</SUBSECTION>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2008-10-04 16:38:43 +0200" MODIFIED_BY="[Empty name]">
<P>Heterogeneity between trial results were tested for using a standard chi-squared test. Tests of heterogeneity are used for examining whether the observed variation in study results is compatible with the variation expected by chance alone. A significance level of alpha set at 0.1 was used for the test of heterogeneity in view of the low power of such tests. Heterogeneity was also examined with I<SUP>2</SUP>, where I<SUP>2</SUP> values of 50% and more indicate a substantial level of heterogeneity (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>). When found, we attempted to determine potential reasons for it by examining individual study characteristics and those of subgroups of the main body of evidence.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2008-10-04 16:39:09 +0200" MODIFIED_BY="[Empty name]">
<P>Funnel plot asymmetry were planned to be assessed statistically to explore publication bias if sufficient randomised clinical trials were identified (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-10-04 16:39:24 +0200" MODIFIED_BY="[Empty name]">
<P>Data were summarised statistically if they were available, sufficiently similar and of sufficient quality. Statistical analyses were be performed according to the statistical guidelines referenced in the newest version of the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> (<LINK REF="REF-Higgins-2005" TYPE="REFERENCE">Higgins 2005</LINK>). Pooled results were analysed using primarily a fixed-effect model.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-10-04 16:39:35 +0200" MODIFIED_BY="[Empty name]">
<P>We planned to perform subgroup analyses to explore whether there were any systematic differences between groups of patients. If the results of at least one of the main outcomes were significant, in order to explore effect size differences and if the amount of data permitted, subgroup analyses were planned to be conducted according to the following:<BR/>
</P>
<UL>
<LI>Weight level (BMI) at baseline;</LI>
<LI>Age;</LI>
<LI>Gender;</LI>
<LI>Different comparison interventions;</LI>
<LI>Duration of intervention.</LI>
</UL>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-10-04 16:40:07 +0200" MODIFIED_BY="[Empty name]">
<P>We performed sensitivity analyses to explore the influence of the following factors on effect size:<BR/>
</P>
<UL>
<LI>repeating the analysis excluding unpublished studies;</LI>
<LI>repeating the analysis taking study quality, as specified above, into account;</LI>
<LI>repeating the analysis excluding any very long or large studies to establish how much they dominate the results.</LI>
<LI>repeating the analysis excluding studies using the following filters: diagnostic criteria, language of publication, source of funding (industry versus other), country.</LI>
</UL>
<P>The robustness of the results was also be tested by repeating the analysis using different measures of effects size (risk difference, odds ratio etc) and different statistical models (fixed and random-effects models).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2008-11-03 12:05:18 +0100" MODIFIED_BY="Gudrun Paletta">
<STUDY_DESCRIPTION MODIFIED="2008-11-03 12:01:59 +0100" MODIFIED_BY="Gudrun Paletta">
<P>From the initial search, 326 records were identified, and from these, 75 full papers were identified for further examination. The other studies were excluded on the basis of their abstracts because they were not relevant to the question under study. See <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> for details of the amended QUOROM (quality of reporting of meta-analyses) statement.</P>
<P>After screening the full text of the selected papers, six studies finally met the inclusion criteria. Two studies were only presented as abstracts of congresses. One of these was a subgroup analysis of the RIO-studies and it was not included in the results. This study is included in <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>. One of the six studies is an one ongoing trial, with an expected end of study in August, 2007 (see <LINK TAG="CHARACTERISTICS_OF_ONGOING_STUDIES" TYPE="SECTION">Characteristics of ongoing studies</LINK> for details). One additional title was selected, but it was not retrieved because the reference was wrong. The other three articles were published in peer review journals.</P>
<SUBSECTION>
<HEADING LEVEL="3">Assessment of publication bias and inter-rater agreement</HEADING>
<P>Two authors (CC and CA) reviewed the studies. There was agreement on the studies to be extracted for closer inspection from the searches. The full papers were obtained, and from these, the studies eligible for the review were selected. The authors completely agreed on the final papers chosen for the review.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Missing data</HEADING>
<P>Some authors were contacted for further information. The authors of the <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> study (Dr Pi-Sunyer and Dr Aronne) were contacted by e-mail to ask whether they could send details about the results, which were only published as placebo subtracted changes from baseline or changes from baseline only presented in figures, but unfortunately we received no answer. Professor Hollander, who presented the results of the <LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK> trial in the '1st International Congress on "Prediabetes" and the Metabolic Syndrome, 2005', was contacted by e-mail for particulars about the methodology and results of the study, but also did not reply. Dr Jensen was contact by e-mail to ask about more information regarding the study entitled "The selective CB1-receptor antagonist rimonabant reduces body weight and waist circumference in obese subjects" which was presented only as an abstract. He replied, and stated that the presented study constituted a subgroup analysis of the results of three RIO-studies (<LINK REF="STD-RIO_x002d_Europe" TYPE="STUDY">RIO-Europe</LINK>, <LINK REF="STD-RIO_x002d_Lipids" TYPE="STUDY">RIO-Lipids</LINK> and <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK>); the abstract publication therefore was not included in the present analysis. With regards to the selected title where the reference was wrong entitled "SR141716, a selective cannabinoid CB1 receptor antagonist, reduces hunger, caloric intake and body weight in over weight or obese men", we got an answer from Dr Belisse, one of authors, informing that the study was part of a series of trials done by the Sanofi company on this product, and that the methods and results are the property of Sanofi. Unfortunately, we got no answer from Sanofi when we asked for unpublished data.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Excluded studies</HEADING>
<P>Excluded studies and the reasons for exclusion are given in the table <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Included studies</HEADING>
<P>Details of the characteristics of the included studies are given in the table <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>. The following gives a brief overview.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Characteristics of included studies</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Methods</HEADING>
<P>All four studies finally selected for the review were randomised controlled trials published in English. The duration of the intervention was 24 months for the <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> and 12 months for the <LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK>, <LINK REF="STD-RIO_x002d_Lipids" TYPE="STUDY">RIO-Lipids</LINK> and <LINK REF="STD-RIO_x002d_Europe" TYPE="STUDY">RIO-Europe</LINK> study. Although the last two described a period of 24 months during which they were conducted, only the first 12-months results are provided. All trials had a run-in, as a single blind period before the randomisation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Participants</HEADING>
<P>The included studies involved 6625 participants. The main inclusion criteria entailed adults (18 years or older), with a body mass index greater than 27 kg/m² and less than 5 kg variation in body weight within the three months before study entry.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Intervention</HEADING>
<P>All trials were multicentric. The <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> was conducted in the USA and Canada, <LINK REF="STD-RIO_x002d_Europe" TYPE="STUDY">RIO-Europe</LINK> in Europe and the USA, <LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK> in the USA and 10 other different countries not specified, and <LINK REF="STD-RIO_x002d_Lipids" TYPE="STUDY">RIO-Lipids</LINK> in eight unspecified different countries.<BR/>The intervention received was placebo, 5 mg of rimonabant or 20 mg of rimonabant once daily in addition to a mild hypocaloric diet (600 kcal/day deficit).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Outcomes</HEADING>
<P>
<I>Primary<BR/>
</I>In all studies the primary outcome assessed was weight change from baseline after one year of treatment and the <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> study also evaluated the prevention of weight regain between the first and second year. All studies evaluated adverse effects, including those of any kind and serious events. Quality of life was measured in only one study, but the results were not described (<LINK REF="STD-RIO_x002d_Europe" TYPE="STUDY">RIO-Europe</LINK>).</P>
<P>
<I>Secondary and additional outcomes<BR/>
</I>These included prevalence of metabolic syndrome after one year and change in cardiometabolic risk factors such as blood pressure, lipid profile, etc.</P>
<P>No study included mortality and costs as outcome.</P>
<P>The timing of outcome measures was variable and could include monthly investigations, evaluations every three months or a single final evaluation after one year.<BR/>
</P>
</SUBSECTION>
</SUBSECTION>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-11-03 12:02:26 +0100" MODIFIED_BY="Gudrun Paletta">
<P>The methodological characteristics of the included studies are summarised in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. There was complete agreement between the two authors regarding quality assessment; therefore a kappa-statistic was not calculated.</P>
<SUBSECTION>
<HEADING LEVEL="3">Overview</HEADING>
<P>All four studies had some methodological weaknesses according to the methodological quality criteria evaluated. None fulfilled all quality criteria.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Randomisation and allocation concealment</HEADING>
<P>All selected trials were described as randomised. However, only two studies reported an appropriate method of randomisation (<LINK REF="STD-RIO_x002d_Europe" TYPE="STUDY">RIO-Europe</LINK> and <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK>). Most studies did not mention any procedure for allocation concealment, with only one reporting adequate allocation concealment (<LINK REF="STD-RIO_x002d_Europe" TYPE="STUDY">RIO-Europe</LINK>). The main characteristics of the participants in the three groups were similar at baseline in all selected studies.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Blinding</HEADING>
<P>The selected trials were described as double-blind. However, no details of the methods employed or at which stage of the process blinding was performed, were reported. No trial reported blinding of outcome assessors (those taking samples or carrying out laboratory tests). None of the included studies specifically reported blinding of either the study participants or the providers of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Power calculation</HEADING>
<P>Power calculations were reported as incorporated in the design of one of the four studies included in this review. The sample size of the <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> study was based on 99% power to detect a 3-kg difference between one dose of rimonabant and placebo after one year with P &lt; 0.025. No other included study reported power calculations.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Descriptions of losses to follow-up</HEADING>
<P>Three of the selected trials described losses to follow-up (<LINK REF="STD-RIO_x002d_Europe" TYPE="STUDY">RIO-Europe</LINK>, <LINK REF="STD-RIO_x002d_Lipids" TYPE="STUDY">RIO-Lipids</LINK> and <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK>). Only one, <LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK>, described the number of patients who discontinued treatment because of adverse events.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Intent-to-treat (ITT) population analyses</HEADING>
<P>All studies reported an intention-to-treat analysis. The method used for missing data was mainly last-observation-carried-forward. No study described the ITT population in detail.<U>
<BR/>
</U>
</P>
</SUBSECTION>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-11-03 12:05:18 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Results of the meta-analyses are reported below. Data from the studies were pooled for meta-analysis at one year.</P>
<SUBSECTION>
<HEADING LEVEL="3">Primary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Weight (kg) change</HEADING>
<P>Comparing rimonabant 20 mg with placebo, meta-analysis of all included studies showed evidence of heterogeneity with a reduction in mean weight of 4.6 kg for the rimonabant group but this result could not be considered (I² = 60.6%). When we performed the analysis excluding the <LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK> study which was only published as an abstract of congress we observed that the heterogeneity was significantly reduced and the pooled data showed a reduction in mean weight of 4.9 kg (-4.9 weighted mean difference [WMD], 95% confidence interval [CI] -5.3 to -4.5). In the comparison between rimonabant 5 mg and placebo, the pooled effect was a weight reduction of 1.3 kg for the rimonabant group excluding the <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> study due to lack of data (-1.3 kg WMD, 95% CI -1.6 to -0.9). Comparing the two intervention groups, there was a pooled effect of weight reduction of 3.3 kg for the rimonabant 20 mg group, also excluding the <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> study (-3.3 kg WMD, 95% CI -3.7 to -2.9). All results were statistically significant (P &lt; 0.0001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Waist circumference (cm) change</HEADING>
<P>The pooled meta-analysis of all included studies showed evidence of a reduction in waist circumference of 3.8 cm for the rimonabant 20 mg group when compared with placebo (-3.8 cm WMD, 95% CI -4.3 to -3.4). In the rimonabant 5 mg versus placebo comparison, the pooled effect was a reduction of 1.2 cm for the rimonabant group excluding the <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> study due to lack of data (-1.2 cm WMD, 95% CI -1.7 to -0.7). Comparing the two intervention groups, the pooled data showed substantial heterogeneity (I² = 53.5%). We performed several sensitivity analysis, but even excluding the <LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK> study which was only published as an abstract of congress, we could not explain the observed heterogeneity. For this reason the pooled data are not reliable. All results were statistically significant (P &lt; 0.0001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects (general)</HEADING>
<P>The combined results of the three trials (excluding the <LINK REF="STD-RIO_x002d_Lipids" TYPE="STUDY">RIO-Lipids</LINK> study) indicated that compared to placebo, patients treated with rimonabant 20 mg reported significantly more general adverse effects: RR = 1.05, 95% CI 1.01 to 1.08 (P = 0.005). There were no statistically significant differences for adverse effects in the meta-analysis comparing the results of rimonabant 5 mg with placebo (also excluding the <LINK REF="STD-RIO_x002d_Lipids" TYPE="STUDY">RIO-Lipids</LINK> study). Comparing the two intervention groups, patients treated with rimonabant 20 mg reported significantly more adverse effects than the rimonabant 5 mg group: RR = 1.04, 95% CI 1.01 to 1.06 (P = 0.008). The <LINK REF="STD-RIO_x002d_Lipids" TYPE="STUDY">RIO-Lipids</LINK> study was not included because it did not provide overall numbers for adverse effects but for single events only (multiple episodes were possible for each patient).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Adverse effects (serious)</HEADING>
<P>The pooled meta-analysis of all included studies showed that compared to placebo, patients treated with rimonabant 20 mg reported significantly more serious adverse effects: RR = 1.37, 95% CI 1.04 to 1.80 (P = 0.03). There were no statistically significant differences for serious adverse effects in the meta-analysis comparing the results of rimonabant 5 mg with placebo and also for the comparison between the two intervention groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Discontinuation due to adverse effects</HEADING>
<P>The pooled meta-analysis of all included studies showed that compared to placebo, patients treated with rimonabant 20 mg reported a significantly greater rate of discontinuation due to adverse effects: RR = 1.92, 95% CI 1.57 to 2.34 (P &lt; 0.00001). There were no statistically significant differences comparing the results of rimonabant 5 mg with placebo. For the comparison between the two intervention groups patients treated with rimonabant 20 mg also reported a significantly greater rate of discontinuation due to adverse effects: RR = 1.58, 95% CI 1.34 to 1.85 (P &lt; 0.00001).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Blood pressure change</HEADING>
<P>Comparing rimonabant 20 mg with placebo, the meta-analysis of the included studies, excluding the <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> study due to lack of data, showed evidence of an average reduction in systolic and diastolic blood pressure of 2 mm Hg (-2 mm Hg WMD, 95% CI -3 to -1) and 1 mm Hg (-1 mm Hg WMD, 95% CI -2 to -0.5) respectively in the rimonabant group. There were no statistically significant differences for the rimonabant 5 mg versus placebo comparison in the same three studies, considering both systolic and diastolic blood pressures.<BR/>Comparing the two intervention groups, the pooled data showed substantial heterogeneity (I² = 55.6%). We performed sensitivity analyses, but even excluding the <LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK> study which was only published as an abstract of congress, we could not explain the observed heterogeneity. For this reason the pooled data are not reliable.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Lipid profile change</HEADING>
<P>Serum triglyceride levels were reported in all studies as well as high density lipoprotein cholesterol and a meta-analysis of these data was carried out.<BR/>The pooled data of the all studies showed a significant lowering of plasma triglycerides in the rimonabant 20 mg group compared with placebo of 19.8 mg/dl (-19.8 mg/dl WMD, 95% CI -24.1 to -15.6; P &lt; 0.00001). There was no statistically significant reduction of plasma triglycerides in the rimonabant 5 mg and placebo comparison in three studies (excluding the <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> study due to lack of data). In the rimonabant 20 mg versus 5 mg comparison the meta-analysis of same three studies showed a statistically significant average reduction of 19.9 mg/dl (-19.9 mg/dl WMD, 95% CI -25.4 to -14.4; P &lt; 0.00001) for the 20 mg group.<BR/>For the high density lipoprotein cholesterol analysis, the pooled data of all studies of the rimonabant 20 mg versus placebo comparison showed an increase of 3.5 mg/dl in the rimonabant group (3.5 mg/dl WMD, 95% CI 3.0 to 4.0). For the rimonabant 5 mg versus placebo comparison, excluding the <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> study, there was an increase of 1.3 mg/dl in the rimonabant group (1.3 mg/dl WMD, 95% CI 0.3 to 1.9). Comparing the two intervention groups, an average increase of 2.3 mg/dl (2.3 mg/dl WMD, 95% CI 1.7 to 3.0) was found favouring the rimonabant group. All analyses were statistically significant (P &lt; 0.00001).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Health-related quality of life</HEADING>
<P>This was measured in only one study, but the results were not described (<LINK REF="STD-RIO_x002d_Europe" TYPE="STUDY">RIO-Europe</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Mortality and costs</HEADING>
<P>No study evaluated mortality or costs as an outcome. The <LINK REF="STD-RIO_x002d_Lipids" TYPE="STUDY">RIO-Lipids</LINK> study described in the results section that there were no deaths in any of the three groups. The <LINK REF="STD-RIO_x002d_Europe" TYPE="STUDY">RIO-Europe</LINK> study mentioned in the results section that two deaths occurred, one in the placebo group (haemorraghic cerebrovascular accident, about 2.5 months after randomisation) and one in the rimonabant 20 mg group (uterine adenocarcinoma, two months after randomisation). The other two studies did not describe mortality.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Heterogeneity</HEADING>
<P>Statistical tests for heterogeneity yielded statistically significant results in weight change in the rimonabant 20 mg with placebo comparison, waist circumference change in the rimonabant 20 mg with rimonabant 5 mg comparison and in diastolic blood pressure comparing the two intervention groups. In general, the studies seemed to be homogeneous, but one of them (<LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK>) was only published as an abstract of congress. This possible source for heterogeneity was investigated in the sensitivity analyses and is described below.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Subgroup analyses</HEADING>
<P>We did not have sufficient data to perform subgroup analyses for initial level of weight, age, sex or duration of treatment.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Sensitivity analyses</HEADING>
<P>Since we observed statistical heterogeneity for some pooled estimates, we performed several sensitivity analyses. Excluding the <LINK REF="STD-RIO_x002d_Diabetes" TYPE="STUDY">RIO-Diabetes</LINK> study, the only trial which was not published in a peer review journal, appeared to significantly reduce the observed heterogeneity in the weight change outcome for the rimonabant 20 mg versus rimonabant 5 mg comparison. In the other two results with substantial heterogeneity (waist circumference change and diastolic blood pressure change in the rimonabant 20 mg versus rimonabant 5 mg comparison), even excluding the same study could not relevantly reduce heterogeneity. The studies appeared to be similar, but exploring the influence of other factors on effect size did not seem to be appropriate.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Assessment of publication bias</HEADING>
<P>Funnel plots were not carried out due to the small number of included studies.</P>
</SUBSECTION>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-11-03 12:10:21 +0100" MODIFIED_BY="Gudrun Paletta">
<SUMMARY_OF_RESULTS MODIFIED="2008-11-03 12:07:22 +0100" MODIFIED_BY="Gudrun Paletta">
<P>In this systematic review, we found a statistically significant effect of rimonabant on body weight, blood pressure and plasma lipids. Compared with placebo, rimonabant 20 mg produced a 4.9 kg greater reduction in body weight in trials with one-year results. Improvements in waist circumference, high-density lipoprotein cholesterol, triglyceride levels and systolic and diastolic blood pressure also were seen with rimonabant 20 mg. However, the results with rimonabant 5 mg were not the same, and even being statistically significant the weight reduction was only 1.3 kg greater when compared with placebo. No clinically relevant effects on plasma lipids and blood pressure were found with 5 mg. Comparing the two interventions groups the results were similar to the rimonabant 20 mg versus placebo comparison, favouring the first group. Rimonabant 20 mg caused significant more adverse effects both of general and serious type, especially of nervous system, psychiatric or gastro-intestinal origin.<BR/>Although the studies were large trials, we detected deficiencies in the methodological quality of all included studies in this review. Methods for concealment of allocation were described in only one study, and the randomisation method was described in only two. Most studies were described as double-blind, but it was unclear which two parties were blinded (patient, treatment administrator or outcome assessor). In spite of the reported deficiencies in the methodological quality, the data were too homogeneous to explore the effects of allocation concealment and blinding on outcomes. Only one study described power calculation, and in the intention-to-treat (ITT) analysis part, no study described the ITT population. The quality of descriptive information on study population and the intervention were generally adequate.</P>
</SUMMARY_OF_RESULTS>
<POTENTIAL_BIASES MODIFIED="2008-11-03 12:07:33 +0100" MODIFIED_BY="Gudrun Paletta">
<P>This is the first systematic review and meta-analysis on the topic of rimonabant related to overweight and obesity. It offers an up-to-date and complete overview of all randomised trials concerning the topic as it is based on an extensive search, including unpublished studies. In addition, strong efforts have been done to minimise missing or incomplete data by attempting to contact all authors.<BR/>Even if this review presents a possibly confusing amount of data and figures, completeness is one of the strengths of a Cochrane systematic review. The way we presented these data, subdivided in subheadings in different tables, makes it possible for the reader to find every specific piece of information obtained from the individuals trials.<BR/>This review will be regularly updated, allowing eventual addition of information or correction of possible errors.</P>
<P>The major methodological limitation of this review is attributed to the quality of the included studies. We observed a high attrition rate in both treatment and placebo groups (approximately 40% in all studies). Authors tried to address this by carrying forward the last observation on record to the end of the study. When the data are analysed in this way, biased results may occur in either direction, depending on the reasons for withdrawal and the differential dropout rates in treatment and placebo groups. If we consider, for example, that patients in the placebo group may drop out of the study early because of weight gain due to lack of efficacy, measuring their weight at the point of withdrawal will likely underestimate their weight at the end of the study period supposing that they should slowly gain weight during the rest of the intervention period. This would underestimate the degree of weight gain in the placebo group and suggest a falsely lower overall treatment effect. On the other hand, if non-responders in the treatment arm drop out early leaving only responders to complete the trial, the treatment effect may be overestimated. Such high attrition rates are difficult to compensate by any form of analysis. Considerable bias may be introduced into the results of these studies, and should be kept in mind when interpreting the results of this review.<BR/>The <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> study reported outcomes in a way that could not contribute to meta-analyses. This problem was not solved by asking authors for additional data, because unfortunately we got no answer.<BR/>Research funded by pharmaceutical companies could be more likely to produce results favouring the tested drug. Consistent evidence also demonstrated that industry ties are associated with both publication delays and data withholding. These restrictions serve to compound bias in biomedical research. Rather, such behaviour appears to arise when investigators are involved in the process of bringing their research results to market (<LINK REF="REF-Bekelman-2003" TYPE="REFERENCE">Bekelman 2003</LINK>). In this review all studies were sponsored by the pharmaceutical company, in which the sponsor was the producer of the evaluated drug. The results should be interpreted with caution since conflict of interests could have influence on the results.<BR/>Health related quality of life is an important question that was not considered in the included studies. The effect of treatment on patient-reported outcomes, including any report coming directly from affected persons concerning their life, health conditions and treatment should be considered in clinical trials.<BR/>Despite a thorough search, including requests to manufacturers, we still cannot rule out publication bias. The included studies are phase III clinical trials evaluating the effects, tolerability and safety of rimonabant. Others studies have probably been done primarily to evaluate the short-term effects of the drug, as indicated by one of the authors contacted. We tried to obtain unpublished studies from the manufacturer, but unfortunately got no answer. Still, we welcome unpublished data for future updates.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2008-11-03 12:10:21 +0100" MODIFIED_BY="Gudrun Paletta">
<P>Although this is the first systematic review concerning rimonabant in overweight and obesity, some reviews have been published recently (<LINK REF="REF-Boyd-2005" TYPE="REFERENCE">Boyd 2005</LINK>; <LINK REF="REF-Cox-2005" TYPE="REFERENCE">Cox 2005</LINK>; <LINK REF="REF-Gelfand-2006" TYPE="REFERENCE">Gelfand 2006</LINK>; <LINK REF="REF-Tonstad-2006" TYPE="REFERENCE">Tonstad 2006</LINK>). They only focused on describing the clinical results in the published studies. The quality of these reviews is limited: selection criteria for the studies were insufficiently specified and there was no mentioning of the criteria used to assess the validity of individual trials. Further, these reviews did not present explicit methods on data extraction, assessment of quality or heterogeneity analyses.<BR/>Presently the approved anti-obesity pharmacotherapy options are limited to orlistat and sibutramine. Padwall (<LINK REF="REF-Padwall-2003" TYPE="REFERENCE">Padwall 2003</LINK>) carried out a systematic review and meta-analysis of long term pharmacotherapy for overweight and obesity. Compared with placebo, those receiving orlistat had a 2.7 kg decrease in body weight, and the treatment with sibutramine produced a weight loss of 4.3 kg. Orlistat-treated patients displayed improvements in total cholesterol, low-density lipoprotein cholesterol, blood pressure, and glycaemic control but had increased rates of gastrointestinal side effects and slightly lower high-density lipoprotein levels. Sibutramine produced small improvements in high-density lipoprotein cholesterol and triglyceride levels, but was associated with a net increase in blood pressure.<BR/>Comparing the results obtained in this review with the results of the review evaluating the other two cited drugs it seems that the weight loss associated with rimonabant use was slightly greater compared to that related to sibutramine use, with more positive impact on cardiometabolic risk factors. The effects compared with orlistat seem to be greater weight loss and less frequent adverse effects. However, in the rimonabant studies the number of discontinuation due to adverse effects was greater when compared with orlistat studies. The authors of the rimonabant studies cited that the adverse effects were transient, based on the occurrence in the first months of the study. Although the number of patients discontinuing therapy due to adverse effects was approximately 10% in all studies, high study attrition rates raise the possibility that some of these events remained uncaptured.<BR/>Considering the figures presented in all studies related to weight loss change during the entire period, the pattern of weight loss observed indicated that approximately after the 36th week, the level of weight loss decreased and the body weight was maintained practically until the end of the studies. The <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> evaluated the data after two years, and the patients who remained on rimonabant 20 mg seemed to maintain their weight loss, while those who were re-randomised to placebo gained significant weight. Since only the <LINK REF="STD-RIO_x002d_North-America" TYPE="STUDY">RIO-North America</LINK> study reported results after two years where the patients were re-randomised after the end of the first year, and the results were only presented as placebo subtracted changes from baseline, we did not include the data of the second year.<BR/>Both the American Food and Drugs Administration (FDA) and the European Agency for the Evaluation of Medicinal Products (EMEA) demand that any anti-obesity drug should produce significantly greater weight loss compared to placebo. The FDA specifically demands that placebo-subtracted weight loss is at least 5%. Moreover, significantly more individuals in the drug treated group should lose 5% or more of their initial body weight compared to placebo. On the other hand, the EMEA demands a weight loss of at least 10% from baseline, which should also be greater than placebo. The secondary outcome of anti-obesity drug trials is to ensure that this weight loss is sustained and able to induce a significant reduction in risk factors for a number of obesity related co-morbidities. Moreover, drug induced weight loss should have a positive impact on health related quality of life.<BR/>
</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>This review suggests that the use of rimonabant after one year could produce a modest weight loss of approximately 5%. Even modest amounts of weight loss may be potentially beneficial. Some caution regarding the observed results should be taken into account since the studies presented some deficiencies in the methodological quality. Studies with longer follow-up after the end of treatment and with more rigor in the quality of methodology should be done before definitive recommendations can be made regarding the role of this medication in the management of obese patients.<BR/>Drug therapy in obesity should always be considered in connection with non-pharmacological interventions, on an individual basis, with stronger consideration given to those individuals with greater degrees of obesity and associated co-morbidities. Efforts focusing on the prevention of obesity in non-obese people and non-pharmacological management in obese people should remain the cornerstone of obesity therapy. With regard to adverse effects, rimonabant is contraindicated for patients with severe depression and/or patients who are treated with antidepressive medications in Europe. Rimonabant is furthermore not recommended for patients with other untreated psychiatric conditions.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Further high quality research is needed to assess the efficacy and safety of rimonabant over longer follow-up periods. Future adequately-powered trials should incorporate appropriate design principles including methods of allocation concealment, randomisation, blinding, minimization of attrition and follow-up of drop-outs. Whilst drop-outs and withdrawals can not always be avoided, every effort should be made to ascertain the reasons for withdrawals so that factors affecting adherence can be further elucidated. Future studies should evaluate the use of medication associated with exercise and behavioural modification, identify subgroups of patients that may derive greater benefit from drug therapy, incorporate health-related quality outcomes and also assess the economic costs of treatment.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We are grateful to Bernd Richter for his valuable contribution and suggestions for this review</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None known</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>CINTIA CURIONI: Protocol and review development, searching for trials, selection of studies, quality assessment, data extraction, data analysis, review development.</P>
<P>CHARLES ANDRÉ: Selection of studies, quality assessment, data extraction, data analysis, review development.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2008-11-03 11:50:01 +0100" MODIFIED_BY="Gudrun Paletta">
<P>In the protocol quality assessment according to the criteria by Schulz and Jadad were planned. We did not persue bias categorisation but preferred an individual component analysis approach instead.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-11-03 11:52:57 +0100" MODIFIED_BY="Gudrun Paletta">
<P>On October 23rd 2008 the European Medicines Agency (EMEA) recommended the suspension of the marketing authorisation for rimonabant from the manufacturer. The EMEA concluded that the benefits of rimonabant no longer outweigh its risk and the marketing authorisation should be suspended across the European Union.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-RIO_x002d_Diabetes" NAME="RIO-Diabetes" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Hollander P</AU>
<TI>Endocannabinoid Blockade for Improving Glycemic Control and Lipids in Patients With Type 2 Diabetes</TI>
<SO>1st International Congress on "Prediabetes" and the Metabolic Syndrome; April 13-16, 2005; Berlin, Germany. Available via &lt;http://www.medscape.com/viewarticle/515508&gt; (last accessed 04/08/2006)</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RIO_x002d_Europe" NAME="RIO-Europe" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S</AU>
<TI>Effect of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study</TI>
<SO>The Lancet</SO>
<YR>2005</YR>
<VL>365</VL>
<PG>1389-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RIO_x002d_Lipids" NAME="RIO-Lipids" YEAR="2005">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Depres JP, Golay A, Sjostrom L</AU>
<TI>Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia</TI>
<SO>The New England Journal of Medicine</SO>
<YR>2005</YR>
<VL>353</VL>
<PG>2121-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-RIO_x002d_North-America" NAME="RIO-North America" YEAR="2006">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pi-Sunyer FX, Aronne LJ, Heshmati HM, Devin J, Rosenstock J</AU>
<TI>Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<PG>761-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Jensen-2004" NAME="Jensen 2004" YEAR="2004">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Jesen M, Abu-Lebdeh H, Geohas J, Brazg R, Block M, Noveck R</AU>
<TI>The selective cb1-receptor antagonist rimonabant reduces body weight and waist circumference in obese subjects</TI>
<SO>International Journal of Obesity</SO>
<YR>2004</YR>
<VL>28 (Suppl. 1)</VL>
<PG>S27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-STRADIVARIUS" NAME="STRADIVARIUS" YEAR="2005">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Bekelman-2003" NAME="Bekelman 2003" TYPE="JOURNAL_ARTICLE">
<AU>Bekelman JE, Li Y, Gross CP</AU>
<TI>Scope and impact of financial conflicts of interest in biomedical research: a systematic review</TI>
<SO>JAMA.</SO>
<YR>2003</YR>
<VL>289</VL>
<PG>454-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bergstrom-2001" NAME="Bergstrom 2001" TYPE="JOURNAL_ARTICLE">
<AU>Bergstrom A, Pisani P, Tenet V, Wolk A, Adami HO</AU>
<TI>Overweight as an avoidable cause of cancer in Europe</TI>
<SO>International Journal of Cancer</SO>
<YR>2001</YR>
<VL>1</VL>
<PG>421-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bj_x00f6_rntorp-1984" NAME="Björntorp 1984" TYPE="JOURNAL_ARTICLE">
<AU>Björntorp P</AU>
<TI>Hazards in subgroups of human obesity</TI>
<SO>European Journal of Clinical Investigation</SO>
<YR>1984</YR>
<VL>14</VL>
<PG>239-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bj_x00f6_rntorp-1985" NAME="Björntorp 1985" TYPE="JOURNAL_ARTICLE">
<AU>Björntorp P</AU>
<TI>Obesity and the risk of cardiovascular disease</TI>
<SO>Annals of Clinical Research</SO>
<YR>1985</YR>
<VL>17</VL>
<PG>3-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bonner-2005" NAME="Bonner 2005" TYPE="JOURNAL_ARTICLE">
<AU>Bonner TI</AU>
<TI>Structure of a cannabinoid receptor and functional antagonist</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>2005</YR>
<VL>39</VL>
<PG>684-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Boyd-2005" NAME="Boyd 2005" TYPE="JOURNAL_ARTICLE">
<AU>Boyd ST, Fremming BA</AU>
<TI>Rimonabant - a selective CB1 antagonist</TI>
<SO>The Annals of Pharmacotherapy</SO>
<YR>2005</YR>
<VL>39</VL>
<PG>684-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Brown-2000" NAME="Brown 2000" TYPE="JOURNAL_ARTICLE">
<AU>Brown CD, Higgins M, Donato KA, Rohde FC, Garrison R, Obarzanek E et al</AU>
<TI>Body mass index and prevalence of risk factors for cardiovascular disease</TI>
<SO>Obesity Research</SO>
<YR>2000</YR>
<VL>8</VL>
<PG>676-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chu-1991" NAME="Chu 1991" TYPE="JOURNAL_ARTICLE">
<AU>Chu SY, Lee NC, Wingo PA, Senie RT, Greenberg RS, Peterson HB</AU>
<TI>The relationship between body mass and breast cancer among women enrolled in the Cancer and Steroid Hormone Study</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1991</YR>
<VL>44</VL>
<PG>1197-206</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chua-1994" NAME="Chua 1994" TYPE="JOURNAL_ARTICLE">
<AU>Chua W, Chediak AD</AU>
<TI>Obstructive sleep apnea. Treatment improves quality of life and may prevent death</TI>
<SO>Postgraduate Medicine</SO>
<YR>1994</YR>
<VL>95</VL>
<PG>123-38</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cicuttini-1996" NAME="Cicuttini 1996" TYPE="JOURNAL_ARTICLE">
<AU>Cicuttini FM, Baker JR, Spector TD</AU>
<TI>The association of obesity with osteoarthritis of the hand and knee in women: a twin study</TI>
<SO>Journal of Rheumatology</SO>
<YR>1996</YR>
<VL>23</VL>
<PG>1221-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cohen-1960" NAME="Cohen 1960" TYPE="JOURNAL_ARTICLE">
<AU>Cohen J</AU>
<TI>A coefficient of agreement for nominal scales</TI>
<SO>Educational and Psychological Measurement</SO>
<YR>1960</YR>
<VL>20</VL>
<PG>37-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Colombo-1998" NAME="Colombo 1998" TYPE="JOURNAL_ARTICLE">
<AU>Colombo G, Agabio R, Diaz G, Lobina C, Reali R, Gessa GL</AU>
<TI>Appetite suppression and weight loss after the cannabinoid antagonist SR 141716</TI>
<SO>Life Sciences</SO>
<YR>1998</YR>
<VL>63</VL>
<PG>PL113-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cox-2005" NAME="Cox 2005" TYPE="JOURNAL_ARTICLE">
<AU>Cox SL</AU>
<TI>Rimonabant hydrochloride: an investigational agent for the management of cardiovascular risk factors</TI>
<SO>Drugs of Today</SO>
<YR>2005</YR>
<VL>41</VL>
<PG>499-508</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curioni-2005" NAME="Curioni 2005" TYPE="JOURNAL_ARTICLE">
<AU>Curioni CC, Lourenço PM</AU>
<TI>Long-term weight loss after diet and exercise - a systematic review</TI>
<SO>International Journal of Obesity and related metabolic disorders</SO>
<YR>2005</YR>
<VL>29</VL>
<PG>1168-74</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Di-Marzo-2004" NAME="Di Marzo 2004" TYPE="JOURNAL_ARTICLE">
<AU>Di Marzo V, Bifulco M, De Petrocellis L</AU>
<TI>The endocannabinoid system and its therapeutic exploitation</TI>
<SO>Nature reviews. Drug discovery</SO>
<YR>2004</YR>
<VL>3</VL>
<PG>771-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Di-Marzo-2005" NAME="Di Marzo 2005" TYPE="JOURNAL_ARTICLE">
<AU>Di Marzo V, Matias I</AU>
<TI>Endocannabinoid control of food intake and energy balance</TI>
<SO>Nature Neuroscience</SO>
<YR>2005</YR>
<VL>8</VL>
<PG>585-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Donahue-1987" NAME="Donahue 1987" TYPE="JOURNAL_ARTICLE">
<AU>Donahue RP, Abbott RD, Bloom E, Reed DM, Yano K</AU>
<TI>Central obesity and coronary heart disease in men</TI>
<SO>Lancet</SO>
<YR>1987</YR>
<VL>1</VL>
<PG>821-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ducimetiere-1986" NAME="Ducimetiere 1986" TYPE="JOURNAL_ARTICLE">
<AU>Ducimetiere P, Richard J, Cambien F</AU>
<TI>The pattern of subcutaneous fat distribution in middle-aged men and risk of coronary heart disease: The Paris Prospective Study</TI>
<SO>International Journal of Obesity</SO>
<YR>1986</YR>
<VL>10</VL>
<PG>229-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dyer-1989" NAME="Dyer 1989" TYPE="JOURNAL_ARTICLE">
<AU>Dyer AR, Elliott P</AU>
<TI>The INTERSALT study: relations of body mass index to blood pressure. INTERSALT Co-operative Research Group</TI>
<SO>Journal of Human Hypertension</SO>
<YR>1989</YR>
<VL>3</VL>
<PG>299-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gelfand-2006" NAME="Gelfand 2006" TYPE="JOURNAL_ARTICLE">
<AU>Gelfand EV, Cannon CP,</AU>
<TI>Rimonabant: a cannabinoid receptor type 1 blocker for management of multiple cardiometabolic risk factors</TI>
<SO>Journal of the American College of cardiology</SO>
<YR>2006</YR>
<VL>47</VL>
<PG>1919&#8211;26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Greenway-1996" NAME="Greenway 1996" TYPE="JOURNAL_ARTICLE">
<AU>Greenway FL</AU>
<TI>Obesity surgery</TI>
<SO>Endocrinology and Metabolism Clinics of North America</SO>
<YR>1996</YR>
<VL>25</VL>
<PG>1005-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Halford-2006" NAME="Halford 2006" TYPE="JOURNAL_ARTICLE">
<AU>Halford JC</AU>
<TI>Obesity drugs in clinical development</TI>
<SO>Current Opinion in Investigational Drugs</SO>
<YR>2006</YR>
<VL>7</VL>
<PG>312-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hart-1993" NAME="Hart 1993" TYPE="JOURNAL_ARTICLE">
<AU>Hart DJ, Spector TD</AU>
<TI>The relationship of obesity, fat distribution, and osteoarthritis in women in the general population: the Chingford Study</TI>
<SO>The Journal of Rheumatololy</SO>
<YR>1993</YR>
<VL>20</VL>
<PG>331-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hey-2005" NAME="Hey 2005" TYPE="COCHRANE_REVIEW">
<AU>Hey k, Ussher MH, Lancaster T</AU>
<TI>Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>3</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JPT, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analysis</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<PG>557-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2005" NAME="Higgins 2005" TYPE="BOOK">
<AU>Higgins JPT, Green S, editors</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions 4.2.5 [updated May 2005] In: The Cochrane Library</SO>
<YR>2005</YR>
<PB>John Wiley &amp; Sons, Ltd</PB>
<CY>Chichester, UK</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kissebah-1985" NAME="Kissebah 1985" TYPE="BOOK_SECTION">
<AU>Kissebah AH, Evans DJ, Peiris A, Wilson CR</AU>
<TI>Endrocrine characteristics in regional obesities:role of sex steroids</TI>
<SO>Metabolic Complications of Human Obesities</SO>
<YR>1985</YR>
<PG>115-30</PG>
<ED>Vague J, Björntorp P, Guy Grand B, Rebuffé-Scrive M, Vague P</ED>
<PB>Elsevier Science Publishers, Amsterdam</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lapidus-1984" NAME="Lapidus 1984" TYPE="JOURNAL_ARTICLE">
<AU>Lapidus L, Bengtsson C, Larsson B, Pennert K, Rybo E, Sjöström L</AU>
<TI>Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow-up of participants in the population study of women in Gothenburg, Sweden</TI>
<SO>British Medical Journal (Clinical Research Ed.)</SO>
<YR>1984</YR>
<VL>289</VL>
<PG>1257-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Larsson-1984" NAME="Larsson 1984" TYPE="JOURNAL_ARTICLE">
<AU>Larsson B, Svärdsudd K, Welin L, Wilhelmsen L, Björntorp P, TibblinG</AU>
<TI>Abdominal adipose tissue distribution, obesity and risk of cardiovascular disease and death: 13 year follow-up of participants in the study of men born in 1913</TI>
<SO>British Medical Journal (Clinical Research Ed.)</SO>
<YR>1984</YR>
<VL>288</VL>
<PG>1401-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Luque-1999" NAME="Luque 1999" TYPE="JOURNAL_ARTICLE">
<AU>Luque CA, Rey JA</AU>
<TI>Sibutramine: a serotonin-norepinephrine reuptake-inhibitor for the treatment of obesity</TI>
<SO>Annals of Pharmacotherapy</SO>
<YR>1999</YR>
<VL>33</VL>
<PG>968-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McNeely-1998" NAME="McNeely 1998" TYPE="JOURNAL_ARTICLE">
<AU>McNeely W, Benfield P</AU>
<TI>Orlistat</TI>
<SO>Drugs</SO>
<YR>1998</YR>
<VL>52</VL>
<PG>241-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Medalie-1974" NAME="Medalie 1974" TYPE="JOURNAL_ARTICLE">
<AU>Medalie JH, Papier C, Herman JB, Goldbourt U, Tamir S, Neufeld HN, et al</AU>
<TI>Diabetes mellitus among 10,000 adult men. I. 5-year incidence and associated variables</TI>
<SO>Israel Journal of Medical Sciences</SO>
<YR>1974</YR>
<VL>10</VL>
<PG>681-97</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NHLBI-1998" NAME="NHLBI 1998" TYPE="JOURNAL_ARTICLE">
<AU>National Institutes of Health. National Heart, Lung, and Blood Institute (NIHLBI)</AU>
<TI>Clinical Guidelines on the identification, evaluation, and treatment of overweight and obesity in adults - the evidence report (Clinical Gdlns)</TI>
<SO>Obesity Research</SO>
<YR>1998</YR>
<VL>6</VL>
<PG>51S-209S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-NIHCD-1985" NAME="NIHCD 1985" TYPE="JOURNAL_ARTICLE">
<AU>National Institutes of Health Consensus Development Conference Statement (NIHCD)</AU>
<TI>Health implications of obesity</TI>
<SO>Annals of Internal Medicine</SO>
<YR>1985</YR>
<VL>103</VL>
<PG>1073-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ohlson-1985" NAME="Ohlson 1985" TYPE="JOURNAL_ARTICLE">
<AU>Ohlson LO, Larsson B, Svardsudd K, Welin L, Eriksson H, Wilhelmsen L, et al</AU>
<TI>The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913</TI>
<SO>Diabetes</SO>
<YR>1985</YR>
<VL>34</VL>
<PG>1055-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Padwall-2003" NAME="Padwall 2003" TYPE="COCHRANE_REVIEW">
<AU>Padwal R, Li SK, Lau DCW</AU>
<TI>Long-term pharmacotherapy for obesity and overweight</TI>
<SO>The Cochrane Database of Systematic Reviews</SO>
<YR>2003</YR>
<NO>4</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rexrode-1997" NAME="Rexrode 1997" TYPE="JOURNAL_ARTICLE">
<AU>Rexrode KM, Hennekens CH, Willett WC, Colditz GA, Stampfer MJ, Rich-Edwards JW, et al</AU>
<TI>A prospective study of body mass index, weight change, and risk of stroke in women</TI>
<SO>JAMA</SO>
<YR>1997</YR>
<VL>277</VL>
<PG>1539 -45</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rinaldi_x002d_Carmona-2004" NAME="Rinaldi-Carmona 2004" TYPE="JOURNAL_ARTICLE">
<AU>Rinaldi-Carmona M, Barth F, Congy C, Martinez S, Oustric D, Perio A et al</AU>
<TI>SR147778 [5-(4-bromophenyl)-1-(2,4-dichlorophenyl)-4-ethyl-N-(1-piperidinyl)-1H-pyrazole-3-carboxamide], a new potent and selective antagonist of the CB1 cannabinoid receptor: biochemical and pharmacological characterization</TI>
<SO>The Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>2004</YR>
<VL>310</VL>
<PG>905-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rowland-2001" NAME="Rowland 2001" TYPE="JOURNAL_ARTICLE">
<AU>Rowland NE, Mukherjee M, Robertson K</AU>
<TI>Effects of the cannabinoid receptor antagonist SR 141716, alone and in combination with dexfenfluramine or naloxone, on food intake in rats</TI>
<SO>Psychopharmacology</SO>
<YR>2001</YR>
<VL>159</VL>
<PG>111-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schottenfeld-1996" NAME="Schottenfeld 1996" TYPE="BOOK">
<AU>Schottenfeld D, Fraumeni JF</AU>
<SO>Cancer Epidemiology and Prevention</SO>
<YR>1996</YR>
<PB>New York: Oxford University Press</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simiand-1998" NAME="Simiand 1998" TYPE="JOURNAL_ARTICLE">
<AU>Simiand J, Keane M, Keane PE, Soubrie P</AU>
<TI>SR 141716, a CB1 cannabinoid receptor antagonist, selectively reduces sweet food intake in marmoset</TI>
<SO>Behavioural Pharmacology</SO>
<YR>1998</YR>
<VL>9</VL>
<PG>179-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stokes-1985" NAME="Stokes 1985" TYPE="BOOK_SECTION">
<AU>Stokes III J, Garrison RJ, Kannel WB</AU>
<TI>The independent contributions of various indices of obesity to the 22-year incidence of coronary heart disease: The Framingham Heart Study</TI>
<SO>Metabolic Complications of Human Obesities</SO>
<YR>1985</YR>
<ED>Vague J, Björntorp P, Guy-Grand B, Rebuffe-Scrive M, Vague</ED>
<PB>Elsevier Science Publishers</PB>
<CY>Amsterdam</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tonstad-2006" NAME="Tonstad 2006" TYPE="JOURNAL_ARTICLE">
<AU>Tonstad S</AU>
<TI>Rimonabant: a cannabinoid receptor blocker for the treatment of metabolic and cardiovascular risk factors</TI>
<SO>Nutrition, Metabolism &amp; Cardiovascular Diseases</SO>
<YR>2006</YR>
<VL>16</VL>
<PG>156-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Vickers-2005" NAME="Vickers 2005" TYPE="JOURNAL_ARTICLE">
<AU>Vickers SP, Kennett GA</AU>
<TI>Cannabinoids and the regulation of ingestive behaviour</TI>
<SO>Current Drug Targets</SO>
<YR>2005</YR>
<VL>6</VL>
<PG>215-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Walker-1996" NAME="Walker 1996" TYPE="JOURNAL_ARTICLE">
<AU>Walker SP, Rimm EB, Ascherio A, Kawachi I, Stampfer MJ, Willett WC</AU>
<TI>Body size and fat distribution as predictors of stroke among US men</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1996</YR>
<VL>144</VL>
<PG>1143-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Werner-2003" NAME="Werner 2003" TYPE="JOURNAL_ARTICLE">
<AU>Werner NA, Koch JE</AU>
<TI>Effects of the cannabinoid antagonists AM281 and AM630 on deprivation-induced intake in Lewis rats</TI>
<SO>Brain Research</SO>
<YR>2003</YR>
<VL>28</VL>
<PG>290-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2000" NAME="WHO 2000" TYPE="OTHER">
<AU>World Health Organization</AU>
<TI>Obesity: preventing and managing the global epidemic</TI>
<SO>Technical Report Series 894, Geneva: WHO</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Willett-1995" NAME="Willett 1995" TYPE="JOURNAL_ARTICLE">
<AU>Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, et al</AU>
<TI>Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>273</VL>
<PG>461-5</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2008-11-03 12:12:57 +0100" MODIFIED_BY="Gudrun Paletta">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2008-11-03 12:12:57 +0100" MODIFIED_BY="Gudrun Paletta" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-RIO_x002d_Diabetes">
<CHAR_METHODS>
<P>DURATION OF INTERVENTION:<BR/>12 months</P>
<P>DURATION OF FOLLOW-UP:<BR/>0 months</P>
<P>RUN-IN PERIOD:<BR/>1- ?</P>
<P>LANGUAGE OF PUBLICATION:<BR/>English</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>WHO PARTCIPATED:</P>
<P>INCLUSION CRITERIA:<BR/>Age: 18 to 70 years old; <BR/>BMI of 27 to 40 kg/m2; <BR/>type 2 diabetes that had been treated with metformin or various sulfonylurea monotherapy for at least 6 months.<BR/>hgA1c between 6.5% and 10%, fasting plasma glucose between 100 mg/dL and 271 mg/dL, <BR/>variation in body weight within the previous three months &lt; 5kg</P>
<P>EXCLUSION CRITERIA: ?</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>NUMBER OF STUDY CENTRES:<BR/>151</P>
<P>COUNTRY/LOCATION: <BR/>USA and 10 other countries (?)</P>
<P>SETTING:<BR/>?</P>
<P>INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY):<BR/>Placebo or rimonabant 20 mg or rimonabant 5 mg - daily in addition to a hypocaloric diet</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PRIMARY:<BR/>weight change in 1 year</P>
<P>SECONDARY:<BR/>change in hgA1c, waist circumference, fasting lipid levels with emphasis on HDL and TG, and change in metabolic syndrome prevalence as defined by the ATP III criteria.</P>
<P>TIMING OF OUTCOME MEASURES:<BR/>body weigh, BP, waist circumference - monthly, the other measures every 3 months</P>
<P>ALL-CAUSE MORTALITY.<BR/>0</P>
<P>DISEASE SPECIFIC MORTALITY:<BR/>0</P>
<P>MORBIDITY/COMPLICATIONS:<BR/>1</P>
<P>QUALITY OF LIFE:<BR/>0</P>
<P>ADVERSE EFFECTS:<BR/>1</P>
<P>COSTS:<BR/>0</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-03 12:12:30 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-RIO_x002d_Europe">
<CHAR_METHODS>
<P>DURATION OF INTERVENTION:<BR/>12 months</P>
<P>DURATION OF FOLLOW-UP:<BR/>0</P>
<P>RUN-IN PERIOD:<BR/>1 - 4 weeks</P>
<P>LANGUAGE OF PUBLICATION:<BR/>English</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-03 12:12:16 +0100" MODIFIED_BY="Gudrun Paletta">
<P>WHO PARTCIPATED:</P>
<P>INCLUSION CRITERIA:<BR/>BMI &gt; 30 or 27 with hypertension or dyslipidaemia<BR/>patients had less than 5 Kg variation within 3 months before</P>
<P>EXCLUSION CRITERIA:<BR/>clinical disorders (endocrine disease, diabetes, cardiovascular, pulmonary, hepatic, renal, neurological, psychological, severe depression); previous history of surgical procedures for weight loss; concomitant use of medications known to alter body weight or appetite was not allowed; marijuana or hashish use.</P>
<P>DIAGNOSTIC CRITERIA:</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>NUMBER OF STUDY CENTRES:<BR/>60 (40 - Europe and 20 - USA)</P>
<P>COUNTRY/LOCATION: <BR/>Europe and USA</P>
<P>SETTING:<BR/>?</P>
<P>INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY):<BR/>Placebo or rimonabant 20 mg or rimonabant 5 mg - once/day in addition to a hypocaloric diet and stimulus for exercising</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-03 12:12:30 +0100" MODIFIED_BY="Gudrun Paletta">
<P>PRIMARY:<BR/>weight change</P>
<P>SECONDARY:<BR/>waist circumference,<BR/>glucose and insuline in serum when fasting, HDL and TG and the prevalence of metabolic syndrome</P>
<P>ADDICIONAL<BR/>changes in total cholesterol and LDL, changes in insulin resistance</P>
<P>TIMING OF OUTCOME MEASURES:<BR/>body weight, waist circumference, BP - monthly<BR/>fasting glucose and insulin - every 3 months<BR/>other measures - 12 months</P>
<P>ALL-CAUSE MORTALITY.<BR/>0</P>
<P>DISEASE SPECIFIC MORTALITY:<BR/>0</P>
<P>MORBIDITY/COMPLICATIONS:<BR/>1</P>
<P>QUALITY OF LIFE:<BR/>1, but not analysed</P>
<P>ADVERSE EFFECTS:<BR/>1</P>
<P>COSTS:<BR/>0</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2008-11-03 12:12:57 +0100" MODIFIED_BY="Gudrun Paletta" STUDY_ID="STD-RIO_x002d_Lipids">
<CHAR_METHODS>
<P>DURATION OF INTERVENTION:<BR/>12 months</P>
<P>DURATION OF FOLLOW-UP:<BR/>0 months</P>
<P>RUN-IN PERIOD:<BR/>1</P>
<P>LANGUAGE OF PUBLICATION:<BR/>English<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-03 12:12:57 +0100" MODIFIED_BY="Gudrun Paletta">
<P>WHO PARTCIPATED:</P>
<P>INCLUSION CRITERIA:<BR/>Age: 18 to 70 years old;<BR/>BMI of 27 to 40 kg/m2;<BR/>TG of 1,7 to 7,9 mmol/L<BR/>chol/HDL &gt;5 (men) and &gt;4,5 (women)<BR/>variation in body weight within the previous three months &lt; 5kg</P>
<P>EXCLUSION CRITERIA:<BR/>history of pharmacologic treatment for dyslipidemia 6 weeks before or treatment with VLCD 6 months before; type 1 or 2 diabetes; clinically significant findings indicating cardiovascular disease, endocrine, pulmonary, neurologic, psychiatric, gastrointestinal, hepatic, hematologic, renal or dermatologic disease; + test for hepatitis B surface antigen or hepatitis C antibody, abnormal thyrotropin level; levels of alanine aminotransferase or aspartate aminotransferase &gt; 2,5 times the upper limit; haemoglobin levels &lt; 11g/dl; neutrophil levels &lt; 1500 ml3; platelet levels &lt; 100,000 ml3; creatinine levels &gt; 150mmol/L; a history of marijuana or hashish use; severe depression; treatment for epilepsy, an eating disorder; malignant disease; BP &gt; than 165 or 105 mm Hg; pregnancy; or lactation; &lt; 80% compliance with a hypocaloric diet and placebo during the post-screening four week single blind run in period.</P>
<P>DIAGNOSTIC CRITERIA:<BR/>?</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>NUMBER OF STUDY CENTRES:<BR/>67</P>
<P>COUNTRY/LOCATION: <BR/>8 countries - ?</P>
<P>SETTING:<BR/>?</P>
<P>INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY):<BR/>Placebo or rimonabant 20 mg or rimonabant 5 mg - daily in addition to a hypocaloric diet</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PRIMARY:<BR/>weight change</P>
<P>SECONDARY:<BR/>changes in HDL, TG, Glucose and insulin during an oral glucose-tolerance test and the prevalence of metabolic syndrom</P>
<P>ADDITIONAL:<BR/>waist circumference, leptin and adiponectin levels and relevant biochemical cardiovascular markers</P>
<P>TIMING OF OUTCOME MEASURES:<BR/>body weigh, BP, waist circumference - monthly, the other measures only 12 months</P>
<P>ALL-CAUSE MORTALITY.<BR/>0</P>
<P>DISEASE SPECIFIC MORTALITY:<BR/>0</P>
<P>MORBIDITY/COMPLICATIONS:<BR/>1</P>
<P>QUALITY OF LIFE:<BR/>0</P>
<P>ADVERSE EFFECTS:<BR/>1</P>
<P>COSTS:<BR/>0</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-RIO_x002d_North-America">
<CHAR_METHODS>
<P>DURATION OF INTERVENTION:<BR/>24 months</P>
<P>DURATION OF FOLLOW-UP:<BR/>0</P>
<P>RUN-IN PERIOD:<BR/>1 - 4 weeks</P>
<P>LANGUAGE OF PUBLICATION:<BR/>English<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>WHO PARTCIPATED:</P>
<P>INCLUSION CRITERIA:<BR/>18 years or older;<BR/>BMI of 30 or 27 with treated or untreated dyslipidemia or hypertension</P>
<P>EXCLUSION CRITERIA:<BR/>weight fluctuation of more than 5 Kg in the previous 3 months; clinically significant cardiac, renal, hepatic, gastrointestinal tract, neuropsychiatric or endocrine disorders, drug-treated or diagnosed type 1 or 2 diabetes, use of medications that alter body weight or appetite, a history of current substance abuse; changes in smoking habits or smoking cessation within the past 6 months</P>
<P>DIAGNOSTIC CRITERIA:</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>NUMBER OF STUDY CENTRES:<BR/>72 (64 - USA and 8 - Canada)</P>
<P>COUNTRY/LOCATION: <BR/>USA and Canada</P>
<P>SETTING:</P>
<P>INTERVENTION (ROUTE, TOTAL DOSE/DAY, FREQUENCY):<BR/>Placebo or rimonabant 20 mg or rimonabant 5 mg - once/day in addition to a hypocaloric diet and stimulus for exercising<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>PRIMARY:<BR/>weight change in 1 year<BR/>prevention of weight regain between the first and second years</P>
<P>SECONDARY:<BR/>changes in HDL in 1 year and the prevalence of metabolic syndrom</P>
<P>ADDITIONAL:<BR/>changes in BP, levels of glucose and insulin, lipids, and insulin resistence</P>
<P>TIMING OF OUTCOME MEASURES:<BR/>in the end of year 1 and 2</P>
<P>ALL-CAUSE MORTALITY.<BR/>0</P>
<P>DISEASE SPECIFIC MORTALITY:<BR/>0</P>
<P>MORBIDITY/COMPLICATIONS:<BR/>1</P>
<P>QUALITY OF LIFE:<BR/>0</P>
<P>ADVERSE EFFECTS:<BR/>1</P>
<P>COSTS:<BR/>0</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BMI - body mass index; hgA1c - hemoglobinaA1c; HDL - high density lipoprotein; TG - triglycerides; BP - blood pressure; LDL - low density lipoprotein; chol/HDL - ratio total cholesterol / HDL; VLCD - very low calory diet</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Jensen-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Subgroup analysis of the results of the RIO-studies</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-STRADIVARIUS">
<CHAR_STUDY_NAME>
<P>STRADIVARIUS (Strategy To Reduce Atherosclerosis Development InVolving Administration of Rimonabant - the Intravascular Ultrasound Study)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Ages Eligible for Study: 18 Years and above, Genders Eligible for Study: Both <BR/>Criteria<BR/>Inclusion Criteria:</P>
<P>Written and signed informed consent <BR/>Indication for coronary angiography <BR/>Abdominal obesity defined by waist circumference &gt; 88 cm in women or &gt; 102 cm in men <BR/>At least one of the two following conditions: *a) Metabolic syndrome as defined by the presence of at least two of the following additional risk factors: 1. Triglyceride level &gt;= 150 mg/dL (1.69 mmol/L); 2. HDL cholesterol &lt; 40 mg/dL (1.03 mmol/L) [men] or 50 mg/dL (1.28 mmol/L) [women]; 3. Fasting glucose &gt;= 110 mg/dL (6.1 mmol/L); 4. High blood pressure (&gt;= 140 mmHg systolic and/or &gt;= 90 mmHg diastolic) at Screening visit, or current treatment by anti-hypertensive medication; *b) Currently smoking (&gt; 10 cigarettes /day) and willing to stop <BR/>Angiographic evidence of coronary heart disease as defined by at least 1 lesion in a native coronary artery that has &gt;= 20% reduction in lumen diameter by angiographic visual estimation <BR/>Presence of at least one coronary artery complying with the definition of &#8220;target vessel&#8221; for IVUS assessment <BR/>Acceptation of the Baseline IVUS tape by the IVUS Core Laboratory <BR/>Exclusion Criteria:</P>
<P>Age &lt; 18 years <BR/>Pregnant or breast-feeding women <BR/>History of very low-calorie diet or surgical procedures for weight loss (eg, stomach stapling, bypass) within 6 months prior to screening visit <BR/>Obesity of known endocrine origin <BR/>Uncontrolled diabetes with HBA1c &gt;10% <BR/>Presence of any severe medical or psychological condition, that in the opinion of the Investigator would compromise the subject&#8217;s safety or successful participation in the study <BR/>Severe congestive heart failure (New York Heart Association [NYHA] Class III or IV) <BR/>Clinically significant heart disease which in the opinion of the Investigator is likely to require coronary artery bypass graft (CABG), percutaneous coronary intervention (PCI), cardiac transplantation, surgical repair and/or replacement during the course of the study <BR/>Angioplasty of a non-qualifying artery which is considered at high risk of acute complication or restenosis, during baseline catheterization <BR/>&gt;50% reduction in lumen diameter of the left main coronary artery by visual angiographic estimation <BR/>Recent ST-elevation myocardial infarction (MI) &lt;= 72 hours prior to randomization <BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Study Type: Interventional<BR/>Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Inhibition of Atherosclerosis Progression Assessed by IVUS (IntraVascular UltraSounds)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Study start: January 2005; Study completion: August 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Sponsored by: Sanofi-Aventis <BR/>Information provided by: Sanofi-Aventis <BR/>ClinicalTrials.gov Identifier: NCT00124332 </P>
<P>
<BR/>
</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Data from "www.clinicaltrials.gov"</P>
<P>The purpose of this study is to determine if rimonabant 20 mg once daily (od) administered during 18-20 months will reduce progression of coronary atherosclerosis as assessed by intravascular ultrasound (IVUS) when administered on top of standard behavioral and pharmacological therapy given as needed, in patients with abdominal obesity associated with current smoking and/or metabolic syndrome. </P>
<P>Study ID Numbers: EFC5827; SR141716</P>
<P>Location Information -<BR/>Ohio: The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States </P>
<P>This study is no longer recruiting patients.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RIO_x002d_Diabetes">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-RIO_x002d_Europe">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RIO_x002d_Lipids">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-RIO_x002d_North-America">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-11-03 12:02:42 +0100" MODIFIED_BY="Gudrun Paletta">
<ADDITIONAL_TABLE ID="TBL-01" MODIFIED="2008-10-04 16:30:15 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE>Study quality (included studies)</TITLE>
<TABLE COLS="5" ROWS="69">
<TR>
<TH>
<P>Characteristic</P>
</TH>
<TH>
<P>RIO-Lipids</P>
</TH>
<TH>
<P>RIO-Europe</P>
</TH>
<TH>
<P>RIO-North America</P>
</TH>
<TH>
<P>RIO-Diabetes</P>
</TH>
</TR>
<TR>
<TD>
<P>Randomised controlled clinical trial</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Non-inferiority / equivalence trial<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Controlled clinical trial<BR/>
</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Design: Parallel study<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Design: Crossover study<BR/>
</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Design: Factorial study<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Crossover study: Wash-out phase<BR/>
</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Crossover study: Carryover effect tested<BR/>
</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Crossover study: Period effect tested<BR/>
</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Method of randomisation<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Unit of randomisation (individuals, cluster - specify)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>individuals</P>
</TD>
<TD>
<P>individuals</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Randomisation stratified for centres<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Concealment of allocation<BR/>
</P>
</TD>
<TD>
<P>double</P>
</TD>
<TD>
<P>double</P>
</TD>
<TD>
<P>double</P>
</TD>
<TD>
<P>double</P>
</TD>
</TR>
<TR>
<TD>
<P>Stated blinding (open; single, double, triple blind)<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Actual blinding: Patient<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Actual blinding: Carer / treatment administrator<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Actual blinding: Outcome assessor<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Actual blinding: Others<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Blinding checked: Patient<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Blinding checked: Carer / treatment administrator<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Primary endpoint defined (power calculation)<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Total number of outcomes<BR/>
</P>
</TD>
<TD>
<P>22</P>
</TD>
<TD>
<P>12</P>
</TD>
<TD>
<P>10</P>
</TD>
<TD>
<P>6</P>
</TD>
</TR>
<TR>
<TD>
<P>Prior publication on design of study<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Outcomes of prior / current publication identical<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Power calculation<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] patients per group calculated<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Non-inferiority trial: Interval for equivalence specified<BR/>
</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Intention-to-treat analysis<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Per-protocol-analysis<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Analysis stratified for centres<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Missing data: Last-observation-carried-forward (LOCF)<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Missing data: Other methods<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>Y: baseline imputed</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Treatment Y (T1) / treatment 2 (T2) / control Y (C1)<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>[n] of screened patients (T1/ T2 / C1 / total)<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>2168</P>
</TD>
<TD>
<P>4604</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of eligible patients (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>1676</P>
</TD>
<TD>
<P>3500</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of randomised patients (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>346 / 345 / 342 / 1033</P>
</TD>
<TD>
<P>599 / 603 / 305 / 1507</P>
</TD>
<TD>
<P>1222 / 1216 / 607 / 3045</P>
</TD>
<TD>
<P>339 / 358 / 348 / 1045<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of patients finishing the study (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>221 / 208 / 214 / 643</P>
</TD>
<TD>
<P>363 / 379 / 178 / 920</P>
</TD>
<TD>
<P>673 / 620 / 309 / 1602</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of ITT patients (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>344 / 340 / 334 / 1018</P>
</TD>
<TD>
<P>599 / 603 / 305 / 1507</P>
</TD>
<TD>
<P>1189 / 1191 / 590 / 2970</P>
</TD>
<TD>
<P>339 / 358 / 348 / 1045<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of patients analysed (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>344 / 340 / 334 / 1018</P>
</TD>
<TD>
<P>599 / 603 / 305 / 1507</P>
</TD>
<TD>
<P>1189 / 1191 / 590 / 2970</P>
</TD>
<TD>
<P>339 / 358 / 348 / 1045<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Drop-outs described<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Withdrawals described<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Losses-to-follow-up described<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of drop-outs (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>125 / 137 / 128 / 390</P>
</TD>
<TD>
<P>236 / 224 / 127 / 587</P>
</TD>
<TD>
<P>549 / 596 / 298 / 1443</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] attrition rate (T1/ T2 / C1 / total)<BR/>
</P>
</TD>
<TD>
<P>36 / 40 / 37 / 38</P>
</TD>
<TD>
<P>40 / 37 / 42 / 39</P>
</TD>
<TD>
<P>45 / 49 / 49 / 47</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Differences to [n] / power calculation<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] of subgroups<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Subgroups: Pre-defined<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Subgroups: Post-hoc<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Adjustment for multiple outcomes / repeated measurements<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Baseline characteristics: Clinically relevant differences<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Treatment identical (apart from intervention)<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Timing of outcomes' measurement comparable between groups<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Compliance measured<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Other important covariates measured<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Co-morbidities measured<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Co-medications measured<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Specific doubts about study quality<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Funding: Commercial<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
</TR>
<TR>
<TD>
<P>Funding: Non-commercial<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Publication status: Peer review journal<BR/>
</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>Y</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Publication status: Journal supplement<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Publication status: Abstract<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
</TR>
<TR>
<TD>
<P>Publication status: Other<BR/>
</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>N</P>
</TD>
<TD>
<P>Y<BR/>(presentation in congress)</P>
</TD>
</TR>
<TR>
<TD>
<P>Notes<BR/>
</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Symbols: yes=Y; no=N; unclear=?</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Abbreviations: T=treatment; C=control; NA=not applied</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Rimonabant 20 mg vs placebo (after one year)</NAME>
<CONT_OUTCOME CHI2="7.617452253280563" CI_END="-4.282056454152432" CI_START="-4.99323752008117" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.637646987116801" ESTIMABLE="YES" I2="60.616753472816214" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="0.0546162269976177" P_Q="1.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2503" TOTAL_2="1602" UNITS="" WEIGHT="100.00000000000001" Z="25.562044613461147">
<NAME>Weight [kg] change</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours Placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-3.197216605283136" CI_START="-4.602783394716863" EFFECT_SIZE="-3.9" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-1.4" ORDER="19166" SD_1="5.5" SD_2="3.7" SE="0.35856954528773455" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="348" WEIGHT="25.601027559397966"/>
<CONT_DATA CI_END="-3.8789434529486204" CI_START="-5.721056547051379" EFFECT_SIZE="-4.8" ESTIMABLE="YES" MEAN_1="-6.6" MEAN_2="-1.8" ORDER="19167" SD_1="7.2" SD_2="6.4" SE="0.46993544489416944" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="14.904856262358996"/>
<CONT_DATA CI_END="-4.566974337860878" CI_START="-6.233025662139123" EFFECT_SIZE="-5.4" ESTIMABLE="YES" MEAN_1="-6.9" MEAN_2="-1.5" ORDER="19168" SD_1="6.1" SD_2="5.0" SE="0.4250209027869505" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="18.22147876137511"/>
<CONT_DATA CI_END="-4.14649814723164" CI_START="-5.253501852768359" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" MEAN_1="-6.3" MEAN_2="-1.6" ORDER="19169" SD_1="7.0" SD_2="4.9" SE="0.2824040937151457" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" WEIGHT="41.27263741686794"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.575366741379893" CI_END="-3.417021751352352" CI_START="-4.259333786746906" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.838177769049629" ESTIMABLE="YES" I2="46.19188047784807" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="0.13419981637238632" P_Q="1.0" P_Z="2.331199161759576E-71" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2503" TOTAL_2="1602" UNITS="" WEIGHT="100.00000000000001" Z="17.86200333722125">
<NAME>Waist circumference [cm] change</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.469965131387281" CI_START="-4.13003486861272" EFFECT_SIZE="-3.3000000000000003" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="-1.9" ORDER="19170" SD_1="5.5" SD_2="5.6" SE="0.4234949596828966" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="348" WEIGHT="25.745026741141697"/>
<CONT_DATA CI_END="-3.1248959695421252" CI_START="-5.075104030457874" EFFECT_SIZE="-4.1" ESTIMABLE="YES" MEAN_1="-6.5" MEAN_2="-2.4" ORDER="19171" SD_1="7.4" SD_2="6.9" SE="0.49751119824107504" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="18.654521685663877"/>
<CONT_DATA CI_END="-3.7628141261449226" CI_START="-5.637185873855076" EFFECT_SIZE="-4.699999999999999" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-2.4" ORDER="19172" SD_1="6.8" SD_2="5.7" SE="0.4781648444805513" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="20.194567349521364"/>
<CONT_DATA CI_END="-2.892208589241307" CI_START="-4.307791410758693" EFFECT_SIZE="-3.5999999999999996" ESTIMABLE="YES" MEAN_1="-6.1" MEAN_2="-2.5" ORDER="19173" SD_1="7.0" SD_2="7.4" SE="0.36112470246477024" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" WEIGHT="35.40588422367308"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.6258244023264322" CI_END="1.0793005936073685" CI_START="1.0139004832489424" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0460895723738868" ESTIMABLE="YES" EVENTS_1="1852" EVENTS_2="1031" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.03314241591945323" LOG_CI_START="0.005995330049758908" LOG_EFFECT_SIZE="0.019568872984606054" METHOD="MH" NO="3" P_CHI2="0.7313141626278048" P_Q="0.0" P_Z="0.00471825689734911" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2157" TOTAL_2="1260" WEIGHT="99.99999999999999" Z="2.825665078894058">
<NAME>Adverse effects (general)</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1487382612107875" CI_START="0.9988604475238341" EFFECT_SIZE="1.0711812235475182" ESTIMABLE="YES" EVENTS_1="288" EVENTS_2="276" LOG_CI_END="0.06022108642469873" LOG_CI_START="-4.951835496749796E-4" LOG_EFFECT_SIZE="0.029862951437511873" ORDER="19174" O_E="0.0" SE="0.03566503753333071" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="348" VAR="0.0012719949022538882" WEIGHT="21.31540492677364"/>
<DICH_DATA CI_END="1.0953490000052375" CI_START="0.9764910725561772" EFFECT_SIZE="1.0342139623107254" ESTIMABLE="YES" EVENTS_1="522" EVENTS_2="257" LOG_CI_END="0.03955251609620892" LOG_CI_START="-0.010331722839324788" LOG_EFFECT_SIZE="0.014610396628442069" ORDER="19175" O_E="0.0" SE="0.029302248881697707" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" VAR="8.586217895249545E-4" WEIGHT="26.652199740110575"/>
<DICH_DATA CI_END="1.0885679687576963" CI_START="0.9972204415479483" EFFECT_SIZE="1.0418935792390234" ESTIMABLE="YES" EVENTS_1="1042" EVENTS_2="498" LOG_CI_END="0.036855551002141426" LOG_CI_START="-0.0012088276808138092" LOG_EFFECT_SIZE="0.01782336166066379" ORDER="19176" O_E="0.0" SE="0.022359204460081206" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" VAR="4.999340240877154E-4" WEIGHT="52.03239533311578"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5148722559658712" CI_END="1.8033385360089167" CI_START="1.035161111748295" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3662891069585283" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="69" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="0.2560772633388687" LOG_CI_START="0.015007948341666424" LOG_EFFECT_SIZE="0.13554260584026753" METHOD="MH" NO="4" P_CHI2="0.6788421316688505" P_Q="0.0" P_Z="0.02752420365424519" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2503" TOTAL_2="1602" WEIGHT="100.0" Z="2.2040019968590014">
<NAME>Adverse effects (serious)</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.411595089695073" CI_START="1.0007984430133463" EFFECT_SIZE="1.847787610619469" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" LOG_CI_END="0.5329574806589636" LOG_CI_START="3.466210346460287E-4" LOG_EFFECT_SIZE="0.2666520508468048" ORDER="19177" O_E="0.0" SE="0.3128582554095996" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="348" VAR="0.09788028797793827" WEIGHT="17.75423769962668"/>
<DICH_DATA CI_END="1.8438348214719777" CI_START="0.7187453311913277" EFFECT_SIZE="1.1511940190172025" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="23" LOG_CI_END="0.26572201252218436" LOG_CI_START="-0.14342496337282298" LOG_EFFECT_SIZE="0.061148524574680715" ORDER="19178" O_E="0.0" SE="0.24033495895092183" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" VAR="0.05776089249394128" WEIGHT="36.55561020727041"/>
<DICH_DATA CI_END="3.2540764951384507" CI_START="0.6755457634696773" EFFECT_SIZE="1.4826589595375723" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.5124277578897283" LOG_CI_START="-0.17034522525164897" LOG_EFFECT_SIZE="0.17104126631903968" ORDER="19179" O_E="0.0" SE="0.40106423007801995" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" VAR="0.16085251664807493" WEIGHT="12.063003960796292"/>
<DICH_DATA CI_END="2.13571009466553" CI_START="0.796369209024586" EFFECT_SIZE="1.304152505957264" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="21" LOG_CI_END="0.32954230040151355" LOG_CI_START="-0.09888553996711298" LOG_EFFECT_SIZE="0.11532838021720028" ORDER="19180" O_E="0.0" SE="0.25166063418454404" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" VAR="0.06333307479816691" WEIGHT="33.627148132306615"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.7720357997724772" CI_END="-0.5524815901458904" CI_START="-2.5911712113277243" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5718264007368072" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="0.4122943221260277" P_Q="1.0" P_Z="0.002508965027210634" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1284" TOTAL_2="995" UNITS="" WEIGHT="100.0" Z="3.0222581244196074">
<NAME>Systolic blood pressure [mmHg] change</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.45578538437963245" CI_START="-4.344214615620368" EFFECT_SIZE="-2.4000000000000004" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="1.6" ORDER="19181" SD_1="12.8" SD_2="13.2" SE="0.9919644600391051" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="348" WEIGHT="27.488676186432023"/>
<CONT_DATA CI_END="1.0051508757478902" CI_START="-2.40515087574789" EFFECT_SIZE="-0.7" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.3" ORDER="19182" SD_1="12.5" SD_2="12.3" SE="0.869990922893432" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="35.73687785288951"/>
<CONT_DATA CI_END="-0.11907611974918053" CI_START="-3.4809238802508196" EFFECT_SIZE="-1.8" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-0.3" ORDER="19183" SD_1="12.3" SD_2="10.1" SE="0.8576299837699736" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="36.774445960678456"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6739940836691927" CI_END="-0.4689606122071417" CI_START="-1.8586403462226067" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1638004792148742" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.06" NO="6" P_CHI2="0.7139110247448602" P_Q="1.0" P_Z="0.0010278853170320981" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1284" TOTAL_2="995" UNITS="" WEIGHT="100.00000000000001" Z="3.2827808719073186">
<NAME>Diastolic blood pressure [mmHg] change</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.04130370311850884" CI_START="-2.4413037031185087" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-0.7" ORDER="19184" SD_1="8.2" SD_2="8.4" SE="0.6333298534614686" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="348" WEIGHT="31.333820774201346"/>
<CONT_DATA CI_END="0.3812679470243925" CI_START="-1.9812679470243926" EFFECT_SIZE="-0.8" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.1" ORDER="19185" SD_1="8.7" SD_2="8.5" SE="0.6026988028056043" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="34.599722637503135"/>
<CONT_DATA CI_END="-0.30952234821125413" CI_START="-2.690477651788746" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-0.2" ORDER="19186" SD_1="8.5" SD_2="7.4" SE="0.6073977181106804" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="34.06645658829553"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="5.5231287647290666" CI_END="-15.547910130143743" CI_START="-24.098943143182346" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-19.823426636663044" ESTIMABLE="YES" I2="45.682961093391" I2_Q="0.0" ID="CMP-001.07" NO="7" P_CHI2="0.137261887558923" P_Q="1.0" P_Z="1.0146321960456129E-19" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2503" TOTAL_2="1602" UNITS="" WEIGHT="100.0" Z="9.087370426190201">
<NAME>Triglycerides levels [mg/dl] change</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-20.50368144539278" CI_START="-49.49631855460722" EFFECT_SIZE="-35.0" ESTIMABLE="YES" MEAN_1="-31.0" MEAN_2="4.0" ORDER="19187" SD_1="113.0" SD_2="77.0" SE="7.396216802427153" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="348" WEIGHT="8.698847693251794"/>
<CONT_DATA CI_END="-8.677500442641275" CI_START="-24.962499557358726" EFFECT_SIZE="-16.82" ESTIMABLE="YES" MEAN_1="-17.71" MEAN_2="-0.89" ORDER="19188" SD_1="56.69" SD_2="60.23" SE="4.1544128471674595" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="27.571582122205523"/>
<CONT_DATA CI_END="-12.174654761868151" CI_START="-34.205345238131855" EFFECT_SIZE="-23.19" ESTIMABLE="YES" MEAN_1="-23.55" MEAN_2="-0.36" ORDER="19189" SD_1="77.0" SD_2="70.3" SE="5.6201773731657765" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="15.065409765252985"/>
<CONT_DATA CI_END="-11.64107975567239" CI_START="-23.89892024432761" EFFECT_SIZE="-17.77" ESTIMABLE="YES" MEAN_1="-7.26" MEAN_2="10.51" ORDER="19190" SD_1="57.39" SD_2="65.54" SE="3.1270575850738846" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" WEIGHT="48.6641604192897"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="2.1707461747790533" CI_END="4.036203586171366" CI_START="2.9935052908539483" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="3.5148544385126574" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.5377334977365198" P_Q="1.0" P_Z="7.3070295673131785E-40" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="2503" TOTAL_2="1602" UNITS="" WEIGHT="100.0" Z="13.213770735643946">
<NAME>High-density lipoprotein [mg/dl] change</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.059539265711661" CI_START="1.940460734288339" EFFECT_SIZE="3.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="3.0" ORDER="19191" SD_1="8.0" SD_2="6.0" SE="0.540591191506156" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="348" WEIGHT="24.21158514124147"/>
<CONT_DATA CI_END="5.531852663098093" CI_START="2.968147336901909" EFFECT_SIZE="4.250000000000001" ESTIMABLE="YES" MEAN_1="10.05" MEAN_2="5.8" ORDER="19192" SD_1="10.05" SD_2="8.89" SE="0.6540184785073511" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" WEIGHT="16.54173715713876"/>
<CONT_DATA CI_END="4.703448357658077" CI_START="2.3365516423419215" EFFECT_SIZE="3.5199999999999996" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="4.68" ORDER="19193" SD_1="8.97" SD_2="6.72" SE="0.6038112776525322" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" WEIGHT="19.40701373075823"/>
<CONT_DATA CI_END="4.34598247802202" CI_START="2.6940175219779796" EFFECT_SIZE="3.52" ESTIMABLE="YES" MEAN_1="6.17" MEAN_2="2.65" ORDER="19194" SD_1="8.55" SD_2="8.45" SE="0.4214273754708071" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" WEIGHT="39.839663970861544"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.3314817202177185" CI_END="2.3420262072426574" CI_START="1.56692334718835" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.9156658225941967" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="115" I2="9.949978659827542" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="0.36959175051311266" LOG_CI_START="0.19504775160109294" LOG_EFFECT_SIZE="0.2823197510571028" METHOD="MH" NO="9" P_CHI2="0.3432850301815362" P_Q="0.0" P_Z="2.2921781525634363E-10" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2503" TOTAL_2="1602" WEIGHT="100.00000000000001" Z="6.340367444831479">
<NAME>Discontinuation due to adverse events</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.566272767267444" CI_START="1.662763150107506" EFFECT_SIZE="2.7554727526781555" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="19" LOG_CI_END="0.6595618506016252" LOG_CI_START="0.22083039117558723" LOG_EFFECT_SIZE="0.44019612088860616" ORDER="19195" O_E="0.0" SE="0.25771303102260446" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="348" VAR="0.06641600635885789" WEIGHT="13.514903336788063"/>
<DICH_DATA CI_END="2.3671108081782455" CI_START="1.0574257648417562" EFFECT_SIZE="1.582101120915812" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="28" LOG_CI_END="0.3742185884123859" LOG_CI_START="0.024249888055361577" LOG_EFFECT_SIZE="0.19923423823387376" ORDER="19196" O_E="0.0" SE="0.2055733469627222" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="305" VAR="0.04226040098145576" WEIGHT="26.744396666420503"/>
<DICH_DATA CI_END="3.3924827901958263" CI_START="1.3519684758366013" EFFECT_SIZE="2.1416184971098264" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="24" LOG_CI_END="0.5305176531948712" LOG_CI_START="0.13096656517823185" LOG_EFFECT_SIZE="0.3307421091865515" ORDER="19197" O_E="0.0" SE="0.23469828691075728" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="342" VAR="0.05508328587884414" WEIGHT="17.39863927471104"/>
<DICH_DATA CI_END="2.431451113360258" CI_START="1.2818826590501617" EFFECT_SIZE="1.7654560369900814" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="44" LOG_CI_END="0.3858655420879042" LOG_CI_START="0.10784827256239554" LOG_EFFECT_SIZE="0.24685690732514984" ORDER="19198" O_E="0.0" SE="0.16330872032696309" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="607" VAR="0.026669738134830243" WEIGHT="42.3420607220804"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Rimonabant 5 mg vs placebo (after one year)</NAME>
<CONT_OUTCOME CHI2="3.064197486089889" CI_END="-0.8568863882135007" CI_START="-1.6406499437753874" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.248768165994444" ESTIMABLE="YES" I2="34.73005545239425" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="0.2160817765839288" P_Q="1.0" P_Z="4.2215013833921266E-10" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1306" TOTAL_2="995" UNITS="" WEIGHT="100.0" Z="6.245609694455834">
<NAME>Weight [kg] change</NAME>
<GROUP_LABEL_1>Rimonabant 5 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.346768176723256" CI_START="-1.4532318232767438" EFFECT_SIZE="-0.8999999999999999" ESTIMABLE="YES" MEAN_1="-2.3" MEAN_2="-1.4" ORDER="19199" SD_1="3.8" SD_2="3.7" SE="0.28226632103475674" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="358" TOTAL_2="348" WEIGHT="50.17597628650797"/>
<CONT_DATA CI_END="-0.7497828972162213" CI_START="-2.4502171027837782" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" MEAN_1="-3.4" MEAN_2="-1.8" ORDER="19200" SD_1="5.7" SD_2="6.4" SE="0.43379220714777544" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="603" TOTAL_2="305" WEIGHT="21.244693280066755"/>
<CONT_DATA CI_END="-0.866957685690334" CI_START="-2.333042314309666" EFFECT_SIZE="-1.6" ESTIMABLE="YES" MEAN_1="-3.1" MEAN_2="-1.5" ORDER="19201" SD_1="4.8" SD_2="5.0" SE="0.3740080532559834" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="345" TOTAL_2="342" WEIGHT="28.57933043342527"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.6725315015802726" CI_END="-0.6778241383423976" CI_START="-1.6882168565993192" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.1830204974708585" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="0.7144332913163944" P_Q="1.0" P_Z="4.439768013234849E-6" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1306" TOTAL_2="995" UNITS="" WEIGHT="100.0" Z="4.58965613294523">
<NAME>Waist circumference [cm] change</NAME>
<GROUP_LABEL_1>Rimonabant 5 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.16645256623920934" CI_START="-1.8335474337607907" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="-2.9" MEAN_2="-1.9" ORDER="19202" SD_1="5.7" SD_2="5.6" SE="0.42528711768976696" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="358" TOTAL_2="348" WEIGHT="36.733286529506806"/>
<CONT_DATA CI_END="-0.5766941546121671" CI_START="-2.4233058453878327" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-3.9" MEAN_2="-2.4" ORDER="19203" SD_1="6.3" SD_2="6.9" SE="0.47108306717406623" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="603" TOTAL_2="305" WEIGHT="29.938446000091297"/>
<CONT_DATA CI_END="-0.22490773920235274" CI_START="-1.9750922607976475" EFFECT_SIZE="-1.1" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="-2.4" ORDER="19204" SD_1="6.0" SD_2="5.7" SE="0.4464838475095784" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="345" TOTAL_2="342" WEIGHT="33.32826747040189"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="1.3706658928031712" CI_END="1.0437483398834495" CI_START="0.9782992080171536" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0104940248597205" ESTIMABLE="YES" EVENTS_1="1804" EVENTS_2="1031" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.018595797732347777" LOG_CI_START="-0.009528298057656839" LOG_EFFECT_SIZE="0.004533749837345447" METHOD="MH" NO="3" P_CHI2="0.503922472181798" P_Q="0.0" P_Z="0.5274439397847093" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2175" TOTAL_2="1260" WEIGHT="100.0" Z="0.6319126817417196">
<NAME>Adverse effects (general)</NAME>
<GROUP_LABEL_1>Rimonabant 5 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabat</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1095647336771592" CI_START="0.9597472281025557" EFFECT_SIZE="1.0319407335438426" ESTIMABLE="YES" EVENTS_1="293" EVENTS_2="276" LOG_CI_END="0.04515264470112878" LOG_CI_START="-0.01784313351793213" LOG_EFFECT_SIZE="0.013654755591598315" ORDER="19205" O_E="0.0" SE="0.037004031960007726" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="358" TOTAL_2="348" VAR="0.001369298381297273" WEIGHT="21.778504098526497"/>
<DICH_DATA CI_END="1.0415496710584788" CI_START="0.9223112524341788" EFFECT_SIZE="0.9801188609481774" ESTIMABLE="YES" EVENTS_1="498" EVENTS_2="257" LOG_CI_END="0.017679986095788608" LOG_CI_START="-0.03512249282567362" LOG_EFFECT_SIZE="-0.008721253364942493" ORDER="19206" O_E="0.0" SE="0.031016437494953034" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="603" TOTAL_2="305" VAR="9.620193948783285E-4" WEIGHT="26.558602890160422"/>
<DICH_DATA CI_END="1.0637401339914707" CI_START="0.9724441516083561" EFFECT_SIZE="1.0170682730923695" ESTIMABLE="YES" EVENTS_1="1013" EVENTS_2="498" LOG_CI_END="0.026835545103988313" LOG_CI_START="-0.012135331230824884" LOG_EFFECT_SIZE="0.007350106936581693" ORDER="19207" O_E="0.0" SE="0.022891685668018316" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1214" TOTAL_2="607" VAR="5.240292727233553E-4" WEIGHT="51.66289301131308"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.4354985817385844" CI_END="1.7335905507858484" CI_START="0.9558862150675733" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.287289909098799" ESTIMABLE="YES" EVENTS_1="137" EVENTS_2="69" I2="12.676430258288564" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.2389465311262814" LOG_CI_START="-0.019593801352888445" LOG_EFFECT_SIZE="0.10967636488669646" METHOD="MH" NO="4" P_CHI2="0.3292246993876261" P_Q="0.0" P_Z="0.09633498554569322" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2520" TOTAL_2="1602" WEIGHT="100.0" Z="1.6628873574340095">
<NAME>Adverse effects (serious)</NAME>
<GROUP_LABEL_1>Rimonabant 5 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.466178438079001" CI_START="0.9460771934853951" EFFECT_SIZE="1.8108761329305136" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="15" LOG_CI_END="0.5398509163347167" LOG_CI_START="-0.02407342666690232" LOG_EFFECT_SIZE="0.2578887448339072" ORDER="19208" O_E="0.0" SE="0.3312519505496692" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="358" TOTAL_2="348" VAR="0.10972785474296048" WEIGHT="17.857462800719684"/>
<DICH_DATA CI_END="1.6671361272911775" CI_START="0.5864461120448009" EFFECT_SIZE="0.9887798036465638" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="23" LOG_CI_END="0.22197106288600335" LOG_CI_START="-0.231771888606937" LOG_EFFECT_SIZE="-0.004900412860466851" ORDER="19209" O_E="0.0" SE="0.26653085577078706" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="603" TOTAL_2="305" VAR="0.07103869707790808" WEIGHT="35.89065537498439"/>
<DICH_DATA CI_END="4.224550921735323" CI_START="0.8862732059923979" EFFECT_SIZE="1.9349693251533742" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.6257805493619045" LOG_CI_START="-0.05243238018405205" LOG_EFFECT_SIZE="0.28667408458892624" ORDER="19210" O_E="0.0" SE="0.3983856320234406" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="345" TOTAL_2="342" VAR="0.15871111180271621" WEIGHT="12.049417856179398"/>
<DICH_DATA CI_END="1.8589556958851787" CI_START="0.6497070523881653" EFFECT_SIZE="1.0989889106327462" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="21" LOG_CI_END="0.2692690394427568" LOG_CI_START="-0.18728241906402737" LOG_EFFECT_SIZE="0.04099331018936475" ORDER="19211" O_E="0.0" SE="0.26818058669305295" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1214" TOTAL_2="607" VAR="0.0719208270790301" WEIGHT="34.20246396811652"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.242427637174595" CI_END="0.21257737905330298" CI_START="-1.802361124280146" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.7948918726134215" ESTIMABLE="YES" I2="10.810945831904213" I2_Q="0.0" ID="CMP-002.05" NO="5" P_CHI2="0.3258843040439756" P_Q="1.0" P_Z="0.12200584016606043" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1306" TOTAL_2="995" UNITS="" WEIGHT="100.00000000000001" Z="1.546408924489228">
<NAME>Systolic blood pressure [mmHg] change</NAME>
<GROUP_LABEL_1>Rimonabant 5 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.07412014289544677" CI_START="-3.9258798571045532" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="1.6" ORDER="19212" SD_1="12.9" SD_2="13.2" SE="0.9826098195148726" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="358" TOTAL_2="348" WEIGHT="27.36561537408046"/>
<CONT_DATA CI_END="1.10320063742423" CI_START="-2.30320063742423" EFFECT_SIZE="-0.6000000000000001" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.3" ORDER="19213" SD_1="12.5" SD_2="12.3" SE="0.8689958850564905" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="603" TOTAL_2="305" WEIGHT="34.989036101178556"/>
<CONT_DATA CI_END="1.542011290713741" CI_START="-1.7420112907137413" EFFECT_SIZE="-0.10000000000000003" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.3" ORDER="19214" SD_1="11.8" SD_2="10.1" SE="0.8377762569443707" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="345" TOTAL_2="342" WEIGHT="37.645348524741"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.4909165704099892" CI_END="0.5811989322396176" CI_START="-0.8057044155733062" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.11225274166684425" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.06" NO="6" P_CHI2="0.4745168864703785" P_Q="1.0" P_Z="0.7510388288068088" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1306" TOTAL_2="995" UNITS="" WEIGHT="100.0" Z="0.3172698821152031">
<NAME>Diastolic blood pressure [mmHg] change</NAME>
<GROUP_LABEL_1>Rimonabant 5 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.5466576802774576" CI_START="-0.9466576802774579" EFFECT_SIZE="0.29999999999999993" ESTIMABLE="YES" MEAN_1="-0.4" MEAN_2="-0.7" ORDER="19215" SD_1="8.5" SD_2="8.4" SE="0.6360615246560317" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="358" TOTAL_2="348" WEIGHT="30.941258047343663"/>
<CONT_DATA CI_END="0.48461914322693256" CI_START="-1.8846191432269328" EFFECT_SIZE="-0.7000000000000001" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.1" ORDER="19216" SD_1="8.8" SD_2="8.5" SE="0.604408628204935" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="603" TOTAL_2="305" WEIGHT="34.26690722019144"/>
<CONT_DATA CI_END="1.2756486107344676" CI_START="-1.0756486107344674" EFFECT_SIZE="0.1" ESTIMABLE="YES" MEAN_1="-0.1" MEAN_2="-0.2" ORDER="19217" SD_1="8.3" SD_2="7.4" SE="0.5998317418114995" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="345" TOTAL_2="342" WEIGHT="34.79183473246489"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.3462557363732939" CI_END="3.423856033251849" CI_START="-8.04327242363875" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-2.3097081951934504" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.07" NO="7" P_CHI2="0.8410300992286905" P_Q="1.0" P_Z="0.4297896838087436" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1306" TOTAL_2="995" UNITS="" WEIGHT="100.00000000000001" Z="0.7895516117037882">
<NAME>Triglycerides levels [mg/dl] change</NAME>
<GROUP_LABEL_1>Rimonabant 5 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.864019930053551" CI_START="-15.864019930053551" EFFECT_SIZE="-5.0" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="4.0" ORDER="19218" SD_1="70.0" SD_2="77.0" SE="5.542969164610959" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="358" TOTAL_2="348" WEIGHT="27.852761254509222"/>
<CONT_DATA CI_END="7.798777867181411" CI_START="-9.558777867181412" EFFECT_SIZE="-0.88" ESTIMABLE="YES" MEAN_1="-1.77" MEAN_2="-0.89" ORDER="19219" SD_1="68.2" SD_2="60.23" SE="4.428029257495803" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="603" TOTAL_2="305" WEIGHT="43.644770916433174"/>
<CONT_DATA CI_END="8.869484853728085" CI_START="-12.609484853728084" EFFECT_SIZE="-1.87" ESTIMABLE="YES" MEAN_1="-2.23" MEAN_2="-0.36" ORDER="19220" SD_1="73.3" SD_2="70.3" SE="5.479429692810567" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="345" TOTAL_2="342" WEIGHT="28.502467829057615"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5307682213746977" CI_END="1.8762468987315146" CI_START="0.6438968140440452" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.26007185638778" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.08" NO="8" P_CHI2="0.7669113291502934" P_Q="1.0" P_Z="6.120740797661842E-5" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1306" TOTAL_2="995" UNITS="" WEIGHT="99.99999999999997" Z="4.008106928606905">
<NAME>High-density lipoprotein [mg/dl] change</NAME>
<GROUP_LABEL_1>Rimonabant 5 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.9608218122854912" CI_START="0.03917818771450876" EFFECT_SIZE="1.0" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="3.0" ORDER="19221" SD_1="7.0" SD_2="6.0" SE="0.4902242183347914" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="358" TOTAL_2="348" WEIGHT="41.12657088555132"/>
<CONT_DATA CI_END="2.774289713352627" CI_START="0.3257102866473722" EFFECT_SIZE="1.5499999999999998" ESTIMABLE="YES" MEAN_1="7.35" MEAN_2="5.8" ORDER="19222" SD_1="8.89" SD_2="8.89" SE="0.6246490869269378" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="603" TOTAL_2="305" WEIGHT="25.330269250402488"/>
<CONT_DATA CI_END="2.42390320596712" CI_START="0.2960967940328809" EFFECT_SIZE="1.3600000000000003" ESTIMABLE="YES" MEAN_1="6.04" MEAN_2="4.68" ORDER="19223" SD_1="7.49" SD_2="6.72" SE="0.5428177325497061" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="345" TOTAL_2="342" WEIGHT="33.543159864046174"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.138478726013895" CI_END="1.5348094579692841" CI_START="0.9557317664048384" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.211142499609289" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="115" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="0.18605446679107815" LOG_CI_START="-0.01966397876569706" LOG_EFFECT_SIZE="0.08319524401269056" METHOD="MH" NO="9" P_CHI2="0.5441676270882099" P_Q="0.0" P_Z="0.11290490970126663" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2520" TOTAL_2="1602" WEIGHT="100.0" Z="1.5852704069251102">
<NAME>Discontinuation due to adverse events</NAME>
<GROUP_LABEL_1>Rimonabant 5 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours rimonabant</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours placebo</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6830961380344207" CI_START="0.8045194402414696" EFFECT_SIZE="1.469218500797448" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="19" LOG_CI_END="0.4286362341590165" LOG_CI_START="-0.09446345723606242" LOG_EFFECT_SIZE="0.16708638846147705" ORDER="19224" O_E="0.0" SE="0.30727134811070284" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="358" TOTAL_2="348" VAR="0.09441568136976872" WEIGHT="13.974417148736984"/>
<DICH_DATA CI_END="1.4522000592414555" CI_START="0.5509431292147862" EFFECT_SIZE="0.8944717127357272" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="28" LOG_CI_END="0.16202645013790795" LOG_CI_START="-0.25889322863080816" LOG_EFFECT_SIZE="-0.04843338924645011" ORDER="19225" O_E="0.0" SE="0.2472503028947574" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="603" TOTAL_2="305" VAR="0.06113271228154928" WEIGHT="26.83293493288731"/>
<DICH_DATA CI_END="2.1347868782109294" CI_START="0.6926264341593138" EFFECT_SIZE="1.2159810126582278" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.3293545246833111" LOG_CI_START="-0.15950093757655326" LOG_EFFECT_SIZE="0.0849267935533789" ORDER="19226" O_E="0.0" SE="0.2871561184050097" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="345" TOTAL_2="342" VAR="0.08245863633743195" WEIGHT="17.37050524485281"/>
<DICH_DATA CI_END="1.9052279887618775" CI_START="0.922972616454952" EFFECT_SIZE="1.3260743801652892" ESTIMABLE="YES" EVENTS_1="114" EVENTS_2="44" LOG_CI_END="0.2799469528918067" LOG_CI_START="-0.03481118380499406" LOG_EFFECT_SIZE="0.12256788454340635" ORDER="19227" O_E="0.0" SE="0.1848904875736058" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1214" TOTAL_2="607" VAR="0.03418449239520568" WEIGHT="41.822142673522904"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Rimonabant 20 mg vs rimonabant 5 mg (after one year)</NAME>
<CONT_OUTCOME CHI2="2.198688640946837" CI_END="-2.86016902230786" CI_START="-3.7243449465367457" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.292256984422303" ESTIMABLE="YES" I2="9.036688380819324" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="0.33308967470521544" P_Q="1.0" P_Z="1.9868700336623494E-50" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1284" TOTAL_2="1306" UNITS="" WEIGHT="100.0" Z="14.9337766452496">
<NAME>Weight [kg] change</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Rimonabant 5 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours T1 20 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours T2 5 mg</GRAPH_LABEL_2>
<CONT_DATA CI_END="-2.29449944371708" CI_START="-3.70550055628292" EFFECT_SIZE="-3.0" ESTIMABLE="YES" MEAN_1="-5.3" MEAN_2="-2.3" ORDER="19228" SD_1="5.5" SD_2="3.8" SE="0.359955877683375" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="358" WEIGHT="37.51022016055411"/>
<CONT_DATA CI_END="-2.465536774007936" CI_START="-3.9344632259920633" EFFECT_SIZE="-3.1999999999999997" ESTIMABLE="YES" MEAN_1="-6.6" MEAN_2="-3.4" ORDER="19229" SD_1="7.2" SD_2="5.7" SE="0.37473302151744403" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="603" WEIGHT="34.61020904887729"/>
<CONT_DATA CI_END="-2.9816687701794544" CI_START="-4.618331229820546" EFFECT_SIZE="-3.8000000000000003" ESTIMABLE="YES" MEAN_1="-6.9" MEAN_2="-3.1" ORDER="19230" SD_1="6.1" SD_2="4.8" SE="0.41752360567614405" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="345" WEIGHT="27.87957079056859"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="1284" TOTAL_2="1306" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Waist circumference [kg] change</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Rimonabant 5 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours T1 20 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours T2 5 mg</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.4684872065112753" CI_START="-3.1315127934887252" EFFECT_SIZE="-2.3000000000000003" ESTIMABLE="YES" MEAN_1="-5.2" MEAN_2="-2.9" ORDER="19231" SD_1="5.5" SD_2="5.7" SE="0.4242490168429583" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="358" WEIGHT="0.0"/>
<CONT_DATA CI_END="-1.8228058765863073" CI_START="-3.377194123413693" EFFECT_SIZE="-2.6" ESTIMABLE="YES" MEAN_1="-6.5" MEAN_2="-3.9" ORDER="19232" SD_1="7.4" SD_2="6.3" SE="0.3965349004084263" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="603" WEIGHT="0.0"/>
<CONT_DATA CI_END="-2.643847997894917" CI_START="-4.556152002105082" EFFECT_SIZE="-3.5999999999999996" ESTIMABLE="YES" MEAN_1="-7.1" MEAN_2="-3.5" ORDER="19233" SD_1="6.8" SD_2="6.0" SE="0.48784161833946305" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="345" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.9832346949769427" CI_END="1.061936929415982" CI_START="1.0088914573404983" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0350744399907592" ESTIMABLE="YES" EVENTS_1="1852" EVENTS_2="1804" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.026098723882923933" LOG_CI_START="0.0038444447168340503" LOG_EFFECT_SIZE="0.014971584299878958" METHOD="MH" NO="3" P_CHI2="0.6116364199829549" P_Q="0.0" P_Z="0.00836096213862236" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2157" TOTAL_2="2175" WEIGHT="100.0" Z="2.6371347101622447">
<NAME>Adverse effects (general)</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Rimonabant 5 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours T1 20 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours T2 5 mg</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1091079224427742" CI_START="0.9714995061986202" EFFECT_SIZE="1.0380259144039385" ESTIMABLE="YES" EVENTS_1="288" EVENTS_2="293" LOG_CI_END="0.04497380750257134" LOG_CI_START="-0.012557415810744104" LOG_EFFECT_SIZE="0.016208195845913615" ORDER="19234" O_E="0.0" SE="0.03379412535838983" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="358" VAR="0.0011420429087385668" WEIGHT="15.865451360575179"/>
<DICH_DATA CI_END="1.106905848447602" CI_START="1.005894927015679" EFFECT_SIZE="1.0551923889212946" ESTIMABLE="YES" EVENTS_1="522" EVENTS_2="498" LOG_CI_END="0.04411068209045192" LOG_CI_START="0.002552617896317288" LOG_EFFECT_SIZE="0.023331649993384593" ORDER="19235" O_E="0.0" SE="0.024411412623370158" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="603" VAR="5.959170662684359E-4" WEIGHT="27.629281358202274"/>
<DICH_DATA CI_END="1.0599489358748244" CI_START="0.9900601175937702" EFFECT_SIZE="1.0244086919270161" ESTIMABLE="YES" EVENTS_1="1042" EVENTS_2="1013" LOG_CI_END="0.025284943187435287" LOG_CI_START="-0.004338433739271032" LOG_EFFECT_SIZE="0.010473254724082115" ORDER="19236" O_E="0.0" SE="0.01740091824482803" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="1214" VAR="3.0279195576318903E-4" WEIGHT="56.50526728122255"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.2568474088525319" CI_END="1.3763495851476295" CI_START="0.8781333631220964" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0993718615815988" ESTIMABLE="YES" EVENTS_1="149" EVENTS_2="137" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.13872875629618697" LOG_CI_START="-0.056439522283315745" LOG_EFFECT_SIZE="0.0411446170064356" METHOD="MH" NO="4" P_CHI2="0.739404772406042" P_Q="0.0" P_Z="0.4085863271437953" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2503" TOTAL_2="2520" WEIGHT="100.0" Z="0.8263839603161548">
<NAME>Adverse effects (serious)</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Rimonabant 5 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours T1 20 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours T2 5 mg</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7627429393177223" CI_START="0.6326706286937127" EFFECT_SIZE="1.056047197640118" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="27" LOG_CI_END="0.24618898378221415" LOG_CI_START="-0.1988223269006297" LOG_EFFECT_SIZE="0.02368332844079221" ORDER="19237" O_E="0.0" SE="0.2614018467366173" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="358" VAR="0.06833092547731397" WEIGHT="19.278264819266564"/>
<DICH_DATA CI_END="1.7056271454833976" CI_START="0.7933750522315149" EFFECT_SIZE="1.163272120200334" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="45" LOG_CI_END="0.23188409930698134" LOG_CI_START="-0.10052146008639049" LOG_EFFECT_SIZE="0.06568131961029544" ORDER="19238" O_E="0.0" SE="0.19525667102172284" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="603" VAR="0.0381251675784853" WEIGHT="32.9209323237011"/>
<DICH_DATA CI_END="1.5235631100660099" CI_START="0.40672499285176905" EFFECT_SIZE="0.7871919683602069" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.18286044857231176" LOG_CI_START="-0.3906991398056122" LOG_EFFECT_SIZE="-0.1039193456166502" ORDER="19239" O_E="0.0" SE="0.3369117413789445" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="345" VAR="0.11350952147899278" WEIGHT="13.96654258321436"/>
<DICH_DATA CI_END="1.7472416736503222" CI_START="0.8114965883227554" EFFECT_SIZE="1.1907479402218497" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="46" LOG_CI_END="0.24235297955288138" LOG_CI_START="-0.09071330168582815" LOG_EFFECT_SIZE="0.07581983893352662" ORDER="19240" O_E="0.0" SE="0.19564478230430005" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="1214" VAR="0.03827688084289695" WEIGHT="33.834260273817975"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="1.9575880568201087" CI_END="0.32756849254035814" CI_START="-1.5926838206136444" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.6325576640366432" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="0.37576407806879464" P_Q="1.0" P_Z="0.19660713165330468" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1284" TOTAL_2="1306" UNITS="" WEIGHT="99.99999999999999" Z="1.2912784754002045">
<NAME>Systolic blood pressure [mmHg] change</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Rimonabant 5 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours T1 20 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours T2 5 mg</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.5084617656657868" CI_START="-2.3084617656657866" EFFECT_SIZE="-0.4" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.4" ORDER="19241" SD_1="12.8" SD_2="12.9" SE="0.9737228748688698" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="358" WEIGHT="25.309856055818713"/>
<CONT_DATA CI_END="1.313312729482921" CI_START="-1.5133127294829212" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-1.0" MEAN_2="-0.9" ORDER="19242" SD_1="12.5" SD_2="12.5" SE="0.7210911734250994" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="603" WEIGHT="46.150887952357095"/>
<CONT_DATA CI_END="0.09724373243513362" CI_START="-3.497243732435134" EFFECT_SIZE="-1.7000000000000002" ESTIMABLE="YES" MEAN_1="-2.1" MEAN_2="-0.4" ORDER="19243" SD_1="12.3" SD_2="11.8" SE="0.9169779376618973" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="345" WEIGHT="28.53925599182418"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="NO" TOTAL_1="1284" TOTAL_2="1306" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Diastolic blood pressure [mmHg] change</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Rimonabant 5 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours T1 20 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours T2 5 mg</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.2601562714074024" CI_START="-2.7398437285925974" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="-1.9" MEAN_2="-0.4" ORDER="19244" SD_1="8.2" SD_2="8.5" SE="0.6325849548115816" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="358" WEIGHT="0.0"/>
<CONT_DATA CI_END="0.8893162499649122" CI_START="-1.089316249964912" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" MEAN_1="-0.9" MEAN_2="-0.8" ORDER="19245" SD_1="8.7" SD_2="8.8" SE="0.5047624638863328" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="603" WEIGHT="0.0"/>
<CONT_DATA CI_END="-0.34731437070206295" CI_START="-2.8526856292979366" EFFECT_SIZE="-1.5999999999999999" ESTIMABLE="YES" MEAN_1="-1.7" MEAN_2="-0.1" ORDER="19246" SD_1="8.5" SD_2="8.3" SE="0.6391370653639359" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="345" WEIGHT="0.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="3.529465926996647" CI_END="-14.403700795294498" CI_START="-25.372296461463982" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-19.88799862837924" ESTIMABLE="YES" I2="43.334202925656975" I2_Q="0.0" ID="CMP-003.07" NO="7" P_CHI2="0.17123255629993417" P_Q="1.0" P_Z="1.1814591827878736E-12" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1284" TOTAL_2="1306" UNITS="" WEIGHT="100.0" Z="7.107520820815895">
<NAME>Triglycerides levels [mg/dl] change</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Rimonabant 5 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours T1 20 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours T2 5 mg</GRAPH_LABEL_2>
<CONT_DATA CI_END="-15.954588819490713" CI_START="-44.04541118050929" EFFECT_SIZE="-30.0" ESTIMABLE="YES" MEAN_1="-31.0" MEAN_2="-1.0" ORDER="19247" SD_1="113.0" SD_2="70.0" SE="7.166157792335827" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="358" WEIGHT="15.24660496824046"/>
<CONT_DATA CI_END="-8.851890757756419" CI_START="-23.028109242243584" EFFECT_SIZE="-15.940000000000001" ESTIMABLE="YES" MEAN_1="-17.71" MEAN_2="-1.77" ORDER="19248" SD_1="56.69" SD_2="68.2" SE="3.6164487195446875" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="603" WEIGHT="59.866140275281836"/>
<CONT_DATA CI_END="-12.196587222084114" CI_START="-34.18341277791589" EFFECT_SIZE="-23.19" ESTIMABLE="YES" MEAN_1="-23.55" MEAN_2="-0.36" ORDER="19249" SD_1="77.0" SD_2="70.3" SE="5.608987136820128" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="345" WEIGHT="24.887254756477695"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.859464946345047" CI_END="2.962205811603855" CI_START="1.6510520005343288" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="MD" EFFECT_SIZE="2.306628906069092" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.08" NO="8" P_CHI2="0.6506831663433632" P_Q="1.0" P_Z="5.345779023483297E-12" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="USER" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="1284" TOTAL_2="1306" UNITS="" WEIGHT="100.0" Z="6.89607816173249">
<NAME>High-density lipoprotein [mg/dl] change</NAME>
<GROUP_LABEL_1>Rimonabant 5 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Rimonabant 20 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours 5 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours 20 mg</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.772949830108218" CI_START="1.6270501698917843" EFFECT_SIZE="2.700000000000001" ESTIMABLE="YES" MEAN_1="10.05" MEAN_2="7.35" ORDER="9" SD_1="10.05" SD_2="8.89" SE="0.5474334419262333" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="603" WEIGHT="37.332619272293954"/>
<CONT_DATA CI_END="3.1184889033676164" CI_START="0.8815110966323834" EFFECT_SIZE="2.0" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="4.0" ORDER="19250" SD_1="8.0" SD_2="7.0" SE="0.5706680899190568" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="358" WEIGHT="34.35452375080962"/>
<CONT_DATA CI_END="3.3920598309247625" CI_START="0.9279401690752358" EFFECT_SIZE="2.1599999999999993" ESTIMABLE="YES" MEAN_1="8.2" MEAN_2="6.04" ORDER="19252" SD_1="8.97" SD_2="7.49" SE="0.6286135054741282" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="345" WEIGHT="28.31285697689642"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.0896899526511974" CI_END="1.8484843171413854" CI_START="1.3438194325922903" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5760803108397374" ESTIMABLE="YES" EVENTS_1="346" EVENTS_2="221" I2="2.9028787362381245" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="0.26681577029573667" LOG_CI_START="0.12834091700864997" LOG_EFFECT_SIZE="0.1975783436521933" METHOD="MH" NO="9" P_CHI2="0.37800267332773874" P_Q="0.0" P_Z="2.2315123909645445E-8" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2503" TOTAL_2="2520" WEIGHT="100.0" Z="5.593021815744925">
<NAME>Discontinuation due to adverse events</NAME>
<GROUP_LABEL_1>Rimonabant 20 mg</GROUP_LABEL_1>
<GROUP_LABEL_2>Rimonabant 5 mg</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours T1 20 mg</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours T2 5 mg</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.9759585972997904" CI_START="1.2432660129761546" EFFECT_SIZE="1.9235145385587864" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="28" LOG_CI_END="0.473626884841141" LOG_CI_START="0.0945640615518776" LOG_EFFECT_SIZE="0.28409547319650935" ORDER="19253" O_E="0.0" SE="0.22266337879135067" STUDY_ID="STD-RIO_x002d_Diabetes" TOTAL_1="339" TOTAL_2="358" VAR="0.04957898025478051" WEIGHT="12.360858088660944"/>
<DICH_DATA CI_END="2.4338604641914303" CI_START="1.260618859264389" EFFECT_SIZE="1.7516193656093488" ESTIMABLE="YES" EVENTS_1="87" EVENTS_2="50" LOG_CI_END="0.38629567604327497" LOG_CI_START="0.10058380002360423" LOG_EFFECT_SIZE="0.2434397380334396" ORDER="19254" O_E="0.0" SE="0.16782857027055037" STUDY_ID="STD-RIO_x002d_Europe" TOTAL_1="599" TOTAL_2="603" VAR="0.028166428999057067" WEIGHT="22.616012111566274"/>
<DICH_DATA CI_END="2.745940505821663" CI_START="1.1641409345669824" EFFECT_SIZE="1.7879210683675504" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="29" LOG_CI_END="0.43869112347857275" LOG_CI_START="0.06600556055410847" LOG_EFFECT_SIZE="0.2523483420163406" ORDER="19255" O_E="0.0" SE="0.21891734448511974" STUDY_ID="STD-RIO_x002d_Lipids" TOTAL_1="346" TOTAL_2="345" VAR="0.04792480371641658" WEIGHT="13.180130741974788"/>
<DICH_DATA CI_END="1.7118863901833796" CI_START="1.0849120104484409" EFFECT_SIZE="1.362808168904624" ESTIMABLE="YES" EVENTS_1="156" EVENTS_2="114" LOG_CI_END="0.23347493922334975" LOG_CI_START="0.03539451705434191" LOG_EFFECT_SIZE="0.13443472813884583" ORDER="19256" O_E="0.0" SE="0.11635342049597845" STUDY_ID="STD-RIO_x002d_North-America" TOTAL_1="1219" TOTAL_2="1214" VAR="0.013538118461113979" WEIGHT="51.842999057797996"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES>
<FIGURE FILENAME="Other figure.jpg" FILE_TYPE="JPG" ID="FIG-01" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>QUOROM (quality of reporting of meta-analyses) flow chart for study selection</P>
</CAPTION>
<FILE>/9j/4AAQSkZJRgABAgAAAQABAAD/2wBDAAgGBgcGBQgHBwcJCQgKDBQNDAsLDBkSEw8UHRofHh0a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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-10-04 16:59:36 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-10-04 16:26:13 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-10-04 16:26:13 +0200" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-04 16:26:13 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="1" ROWS="2">
<TR>
<TH>
<P>Search terms</P>
</TH>
</TR>
<TR>
<TD>
<P>Unless otherwise stated, search terms are free text terms; MeSH = Medical subject heading (Medline medical index term); exp = exploded MeSH; the dollar sign ($) stands for any character(s); the question mark (?) = to substitute for one or no characters; tw = text word; pt = publication type; sh = MeSH; adj = adjacent.</P>
<P>
<B>MEDLINE:</B>
</P>
<P>Obesity<BR/>1. exp Obesity/<BR/>2. exp Weight Gain/<BR/>3. exp Weight Loss/<BR/>4. body mass index/<BR/>5. (overweight or over weight).tw.<BR/>6. fat overload syndrom$.tw.<BR/>7. (overeat or over eat).tw.<BR/>8. (overfeed or over feed).tw.<BR/>9. (adipos$ or obes$).tw.<BR/>10. (weight adj (cyc$ or reduc$ or los$ or maint$ or decreas$ or watch$ or control$ or gain or chang$)).tw.<BR/>11. body mass inde$.tw.<BR/>12. or/1-11<BR/>
<BR/>Rimonabant<BR/>13. rimonabant.tw.<BR/>14. SR141716A.ti,ab.<BR/>15. acomplia.tw.<BR/>16. 13 or 14 or 15<BR/>
<BR/>Obesity and Rimonabant<BR/>17. 12 and 16<BR/>
<BR/>Controlled Clinical Trials<BR/>18. limit 17 to humans [Limit not valid in: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations; records were retained]<BR/>19. randomized controlled trial.pt.<BR/>20. controlled clinical trial.pt.<BR/>21. randomized controlled trials.sh.<BR/>22. random allocation.sh.<BR/>23. double-blind method.sh.<BR/>24. single-blind method.sh.<BR/>25. or/19-24<BR/>26. limit 25 to animal<BR/>27. limit 25 to human [Limit not valid in: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations; records were retained]<BR/>28. 26 not 27<BR/>29. 25 not 28<BR/>30. clinical trial.pt.<BR/>31. exp clinical trials/<BR/>32. (clinic$ adj25 trial$).tw.<BR/>33. ((singl$ or doubl$ or trebl$ or tripl$) adj (mask$ or blind$)).tw.<BR/>34. placebos.sh.<BR/>35. placebo$.tw.<BR/>36. random$.tw.<BR/>37. research design.sh.<BR/>38. (latin adj square).tw.<BR/>39. or/30-38<BR/>40. limit 39 to animal<BR/>41. limit 39 to human [Limit not valid in: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations; records were retained]<BR/>42. 40 not 41<BR/>43. 39 not 42<BR/>44. comparative study.sh.<BR/>45. exp evaluation studies/<BR/>46. follow-up studies.sh.<BR/>47. prospective studies.sh.<BR/>48. (control$ or prospectiv$ or volunteer$).tw.<BR/>49. cross-over studies.sh.<BR/>50. or/ 44-49<BR/>51. limit 50 to animal<BR/>52. limit 50 to human [Limit not valid in: Ovid MEDLINE(R) In-Process &amp; Other Non-Indexed Citations; records were retained]<BR/>53. 51 not 52<BR/>54. 50 not 53<BR/>55. 29 or 43 or 54<BR/>
<BR/>Obesity and Rimonabant and Controlled Clinical Trials<BR/>56.18 and 55</P>
</TD>
</TR>
</TABLE>
<P/>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-10-04 16:29:11 +0200" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-10-04 16:26:44 +0200" MODIFIED_BY="[Empty name]">Baseline characteristics</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-04 16:29:11 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="5" ROWS="19">
<TR>
<TH>
<P>Characteristic</P>
</TH>
<TH>
<P>RIO-Lipids</P>
</TH>
<TH>
<P>RIO-Europe</P>
</TH>
<TH>
<P>RIO-North America</P>
</TH>
<TH>
<P>RIO-Diabetes</P>
</TH>
</TR>
<TR>
<TD>
<P>[n] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>346 / 345 / 342 / 1033</P>
</TD>
<TD>
<P>599 / 603 / 305 / 1507</P>
</TD>
<TD>
<P>1219 / 1214 / 607 / 3040</P>
</TD>
<TD>
<P>339 / 358 / 348 / 1045</P>
</TD>
</TR>
<TR>
<TD>
<P>Sex [n,%] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 M - 133, 38.4%, F - 213, 61.6% T2 M - 130, 37.7%, F - 215, 62.3% C M - 144, 42.1%; F - 198, 57.9%</P>
</TD>
<TD>
<P>T1 M - 121, 20.2%, F - 478, 79.8% T2 M - 127, 21.1%, F - 476, 78.9% C M - 61, 20%; F - 244, 80%</P>
</TD>
<TD>
<P>T1 M - 230, 18.9%, F - 989, 81.1%<BR/>T2 M - 245, 20.2%, F - 969, 79.8%<BR/>C M - 113, 18.6%; F - 494, 81.4%</P>
</TD>
<TD>
<P>T1 M - 169, 50%, F - 170, 50%<BR/>T2 M - 172, 48%, F - 186, 52%<BR/>C M - 188, 54%; F - 160, 46%"<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Age, years [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 48,4 (10,0)<BR/>T2 48,1 (10,2)<BR/>C 47,0 (10,1)"</P>
</TD>
<TD>
<P>T1 44,6 (11,9)<BR/>T2 45,4 (11,2)<BR/>C 45,0 (11,6)</P>
</TD>
<TD>
<P>T1 45,6 (11,8)<BR/>T2 44,4 (11,3)<BR/>C 44,8 (11,6)<BR/>
</P>
</TD>
<TD>
<P>T1 56,0 (8,5)<BR/>T2 55,9 (8,6)<BR/>C 54,8 (8,6)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Ethnic groups (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>T1 white 555 (92,7%)<BR/>T2 white 565 (93,7%)<BR/>C1 white 290 (95,1%)</P>
</TD>
<TD>
<P>T1 white 1027 (84.2%) black 132 (10,8%)<BR/>T2 white 1010 (11,5%) black 140 (11,5%)<BR/>C1 white 516 (85,0%) black 67 (11.0%)"</P>
</TD>
<TD>
<P>T1 caucasian 302 (89,1%)<BR/>T2 caucasian 315 (88,0%)<BR/>C1 caucasian 308 (88,5%)"<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Duration of disease [mean,SD] (T1/ T2 / C1 / total)<BR/>
</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Weigh [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 - 95.3 (15.1)<BR/>T2 - 96.0 (14.6)<BR/>C - 97.0 (15.4)</P>
</TD>
<TD>
<P>T1 - 101.7 (19.5)T2 - 100.9 (19.8)C - 100.0 (20.3)</P>
</TD>
<TD>
<P>T1 - 103.0 (20.3)<BR/>T2 - 105.5 (21.9)<BR/>C - 105.0 (21.8)</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Body mass index [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 - 33.9 (3.3)<BR/>T2 - 34.1 (3.5)<BR/>C - 34.0 (3.5)</P>
</TD>
<TD>
<P>T1 - 36,0 (5,8)<BR/>T2 - 36,0 (5,9)<BR/>C - 35,7 (5,9)</P>
</TD>
<TD>
<P>T1 - 37.2 (6.2)<BR/>T2 - 38.0 (6.7)<BR/>C - 37.6 (6.4)</P>
</TD>
<TD>
<P>T1 - 34.1 (3.6)<BR/>T2 - 34.4 (3.6)<BR/>C - 34.2 (3.6)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Pharmaco-naive patients [n,%] (T1/ T2 / C1 / total)<BR/>
</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Co-morbidity (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>Metabolic syndrom<BR/>T1 - 183 (52,9%)<BR/>T2 - 193 (55,9%)<BR/>C - 178 (51,9%)</P>
</TD>
<TD>
<P>Metabolic syndrom<BR/>T1 - 251 (42,4%)<BR/>T2 - 243 (40,8%)<BR/>C - 121 (40,6%)<BR/>Hypertension<BR/>T1 - 237 (39,6%)<BR/>T2 - 264 (43,8%)<BR/>C - 116 (38,0%)</P>
</TD>
<TD>
<P>Metabolic syndrom<BR/>T1 - 419 (34,6%)<BR/>T2 - 438 (36,3%)<BR/>C - 192 (31,8%)<BR/>Hypertension<BR/>T1 - 390 (32,0%)<BR/>T2 - 367 (30,2%)<BR/>C - 168 (63,9%)</P>
</TD>
<TD>
<P>Metabolic syndrom<BR/>T1 - 269 (79,2%)<BR/>T2 - 285 (79,5%)<BR/>C - 276 (79,2%)<BR/>Hypertension<BR/>T1 - 216 (63,7%)<BR/>T2 - 218 (60.9%)<BR/>C - 206 (59,2%)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Co-medication (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>Anti-diabetic treatment<BR/>Metformin<BR/>T1 - 218 (64,3%)<BR/>T2 - 230 (64,2%)<BR/>C - 230 (66,1%)<BR/>Sulfonylureas<BR/>T1 - 121 (35,7%)<BR/>T2 - 128 (35.8%)<BR/>C - 118 (33,9%)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>HbA1c [mean,SD] (T1/ T2 / C1 / total)<BR/>
</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Smoker status</P>
</TD>
<TD>
<P>T1 - 53 (15,3%)<BR/>T2 - 58 (16,8%)<BR/>C - 61 (17,8%)</P>
</TD>
<TD>
<P>T1 - 102 (17,0%)<BR/>T2 - 136 (22,6%)<BR/>C - 60 (19,7%)</P>
</TD>
<TD>
<P>T1 - 118 (9,7%)<BR/>T2 - 102 (8,4%)<BR/>C - 64 (10,5%)</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Blood pressure systolic mm Hg [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 - 124.9 (12.7)<BR/>T2 - 123.8 (13.5)<BR/>C - 124.0 (13.8)</P>
</TD>
<TD>
<P>T1 - 127.0 (14.1)<BR/>T2 - 127.0 (14.8)<BR/>C - 126.0 (13.7)</P>
</TD>
<TD>
<P>T1 - 121.7 (12.7)<BR/>T2 - 121.9 (12.7)<BR/>C - 121.7 (12.4)</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Blood pressure diastolic mm Hg [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 - 78.2 (7.7)<BR/>T2 - 78.1 (8.9)C - 78.2 (8.4)</P>
</TD>
<TD>
<P>T1 - 79.4 (8.8)<BR/>T2 - 79.6 (9.1)<BR/>C - 79.6 (8.5)</P>
</TD>
<TD>
<P>T1 - 77.7 (8.2)<BR/>T2 - 78.2 (8.1)<BR/>C - 78.1 (7.8)</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Note</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Symbols: unclear=?</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Abbreviations: T=treatment; C=control; NA=not applied</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-10-04 16:59:36 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-10-04 16:26:53 +0200" MODIFIED_BY="[Empty name]">Adverse events</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-04 16:59:36 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="5" ROWS="33">
<TR>
<TH>
<P>Characteristic</P>
</TH>
<TH>
<P>RIO-Lipids</P>
</TH>
<TH>
<P>RIO-Europe</P>
</TH>
<TH>
<P>RIO-North America</P>
</TH>
<TH>
<P>RIO-Diabetes</P>
</TH>
</TR>
<TR>
<TD>
<P>[n] adverse events (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>407 / 367 / 340 / 1114</P>
</TD>
<TD>
<P>522 / 498 / 257 / 1277</P>
</TD>
<TD>
<P>1042 / 1013 / 498 / 2553</P>
</TD>
<TD>
<P>288 / 293 / 276 / 857</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] adverse events (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>117.6 / 106.4 / 99.4 / 107.8</P>
</TD>
<TD>
<P>87.1 / 82.6 / 84.3 / 84.7</P>
</TD>
<TD>
<P>85.5 / 83.4 / 82.0 / 84.0</P>
</TD>
<TD>
<P>85 / 81.8 / 79.3 / 82</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] nausea (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>44/ 25 / 11 / 80</P>
</TD>
<TD>
<P>77 / 31 / 13 / 121</P>
</TD>
<TD>
<P>117 / 69 / 29 / 215</P>
</TD>
<TD>
<P>41 / 22 / 20 / 83</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] nausea (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>12.7 / 7.2 / 3.2 / 7.7</P>
</TD>
<TD>
<P>12.9 / 5.1 / 4.3 / 8.0</P>
</TD>
<TD>
<P>11.2 / 6.8 / 5.8 / 7.1</P>
</TD>
<TD>
<P>12.1 / 6.1 / 5.7 / 7.9</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] dizziness (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>36 / 29 / 23 / 88</P>
</TD>
<TD>
<P>52 / 42 / 15 / 109</P>
</TD>
<TD>
<P>58 / 46 / 20 / 114</P>
</TD>
<TD>
<P>31 / 11 / 17 / 59</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] dizziness (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>10.4 / 8.4 / 6.7 / 8.5</P>
</TD>
<TD>
<P>8.7 / 7.0 / 4.9 / 7.2</P>
</TD>
<TD>
<P>5.6 / 4.5 / 4.0 / 4.1</P>
</TD>
<TD>
<P>9.1 / 3.1 / 4.9 / 5.6</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] serious adverse events (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>15 / 19 / 10 / 44</P>
</TD>
<TD>
<P>52 / 45 / 23 / 120</P>
</TD>
<TD>
<P>55 / 46 / 21 / 122</P>
</TD>
<TD>
<P>27 / 27 / 15 / 69</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] serious adverse events (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>4.3 / 5.5 / 2.9 / 4.3</P>
</TD>
<TD>
<P>8.7 / 7.5 / 7.5 / 8.0</P>
</TD>
<TD>
<P>4.5 / 3.8 / 3.5 / 4.0</P>
</TD>
<TD>
<P>8.0 / 7.5 / 4.3 / 6.6</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] psychiatric disorders (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>1/ 1 / 1 / 3</P>
</TD>
<TD>
<P>9 / 2 / 1 / 12</P>
</TD>
<TD>
<P>76 / 44 / 14 / 134</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] psychiatric disorders (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>0.3 / 0.3 / 0.3 / 0.3</P>
</TD>
<TD>
<P>1.5 / 0.3 / 0.3 / 0.8</P>
</TD>
<TD>
<P>6.2 / 3.6 / 2.3 / 4.4</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] nervous system disorders (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>2 / 0 / 2 / 4</P>
</TD>
<TD>
<P>3 / 7 / 3 / 13</P>
</TD>
<TD>
<P>27 / 14 / 6 / 47</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] nervous system disorders (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>0.6 / 0 / 0.6 / 0.4</P>
</TD>
<TD>
<P>0.5 / 1.2 / 1.0 / 0.9</P>
</TD>
<TD>
<P>2.2 / 1.2 / 1.0 / 1.6</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] neoplasms (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>2 / 3 / 0 / 5</P>
</TD>
<TD>
<P>7 / 5 / 2 / 14</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] neoplasms (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>0.6 / 0.9 / 0 / 0.5</P>
</TD>
<TD>
<P>1.2 / 0.8 / 0.7 / 0.9</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] discontinuation due to adverse events (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>52 / 29 / 24 / 105</P>
</TD>
<TD>
<P>87 / 50 / 28 / 165</P>
</TD>
<TD>
<P>156 / 114 / 44 / 314</P>
</TD>
<TD>
<P>51 / 28 / 19 / 98</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] discontinuation due to adverse events (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>15.0 / 8.4 / 7.0 / 10.2</P>
</TD>
<TD>
<P>14.5 / 8.3 / 9.2 / 10.9</P>
</TD>
<TD>
<P>12.8 / 9.4 / 7.2 / 10.3</P>
</TD>
<TD>
<P>15.0 / 7.8 / 5.5 / 9.4</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] hospitalisation (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] hospitalisation (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] out-patient treatment (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] out-patient treatment (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] hypoglycaemic episodes (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] hypoglycaemic episodes (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] severe hypoglycaemic episodes (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] severe hypoglycaemic episodes (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] nocturnal hypoglycaemic episodes (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] nocturnal hypoglycaemic episodes (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>[n] with symptoms (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>[%] with symptoms (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
<TD>
<P>NA</P>
</TD>
</TR>
<TR>
<TD>
<P>Notes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Symbols: unclear=?</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Abbreviations: T=treatment, C=control, NA=not applied</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2008-10-04 16:29:57 +0200" MODIFIED_BY="[Empty name]" NO="4">
<TITLE MODIFIED="2008-10-04 16:27:26 +0200" MODIFIED_BY="[Empty name]">Primary outcome data</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-04 16:29:57 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="5" ROWS="9">
<TR>
<TH>
<P>Characteristic</P>
</TH>
<TH>
<P>RIO-Lipids</P>
</TH>
<TH>
<P>RIO-Europe</P>
</TH>
<TH>
<P>RIO-North America</P>
</TH>
<TH>
<P>RIO-Diabetes</P>
</TH>
</TR>
<TR>
<TD>
<P>Weight change [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 -6.9 (6.1)<BR/>T2 -3.1 (4.8)<BR/>C -1.5 (5.0)</P>
</TD>
<TD>
<P>T1 -6.6 (7.2)<BR/>T2 -3.4 (5.7)<BR/>C -1.8 (6.4)</P>
</TD>
<TD>
<P>T1 -6.3 (?)<BR/>T2 -2.9 (?)<BR/>C -1.6 (?)</P>
</TD>
<TD>
<P>T1 -5.3 (0.3)<BR/>T2 -2.3 (0.2)<BR/>C -1.4 (0.2)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Waist circumference change [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 -7.1 (6.8)<BR/>T2 -3.5 (6.0)<BR/>C -2.4 (5.7)</P>
</TD>
<TD>
<P>T1 -6.5 (7.4)<BR/>T2 -3.9 (6.3)<BR/>C -2.4 (6.9)</P>
</TD>
<TD>
<P>T1 -6.1 (?)<BR/>T2 -3.1 (?)<BR/>C -2.5 (?)</P>
</TD>
<TD>
<P>T1 -5.2 (0.3)<BR/>T2 -2.9 (0.3)<BR/>C -1.9 (0.3)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Adverse effects - see under Additional table - Table 04</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Morbidity - see under Additional table - Table 04</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Notes</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Symbols: unclear=?</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Abbreviations: T=treatment; C=control</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2008-10-04 16:29:46 +0200" MODIFIED_BY="[Empty name]" NO="5">
<TITLE MODIFIED="2008-10-04 16:27:38 +0200" MODIFIED_BY="[Empty name]">Secondary outcome data</TITLE>
<APPENDIX_BODY MODIFIED="2008-10-04 16:29:46 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="5" ROWS="11">
<TR>
<TH>
<P>Characteristic</P>
</TH>
<TH>
<P>RIO-Lipids</P>
</TH>
<TH>
<P>RIO-Europe</P>
</TH>
<TH>
<P>RIO-North America</P>
</TH>
<TH>
<P>RIO-Diabetes</P>
</TH>
</TR>
<TR>
<TD>
<P>Total cholesterol / HDL ratio change [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 -0.72 (0.93)<BR/>T2 -0.47 (0.82)<BR/>C -0.40 (0.90)</P>
</TD>
<TD>
<P>T1 -0.71 (0.78)<BR/>T2 -0.52 (0.80)<BR/>C -0.42 (0.83)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Triglycerides change [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 -12.6 (41.2)<BR/>T2 +1.2 (39.4)<BR/>C -0.2 (38.7)</P>
</TD>
<TD>
<P>T1 -0.20 (0.64)<BR/>T2 -0.02 (0.77)<BR/>C -0.20 (0.64)</P>
</TD>
<TD>
<P>T1 -5.3 (?)<BR/>T2 -3.7 (?)<BR/>C +7.9 (?)</P>
</TD>
<TD>
<P>T1 -31.0 (113.0)<BR/>T2 -1.0 (70.0)<BR/>C +4.0 (77.0)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>HDL change [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 +19.1 (20.9)<BR/>T2 +14.2 (17.6)<BR/>C +11.0 (15.8)</P>
</TD>
<TD>
<P>T1 +0.26 (0.26)<BR/>T2 +0.19 (0.23)<BR/>C +0.15 (0.23)</P>
</TD>
<TD>
<P>T1 +12.6 (?)<BR/>T2 +7.6 (?)<BR/>C +5.4 (?)</P>
</TD>
<TD>
<P>T1 +6.0 (8.0)<BR/>T2 +4.0 (7.0)<BR/>C +3.0 (6.0)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>LDL change [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 +7.2 (28.4)<BR/>T2 +6.6 (21.4)<BR/>C +7.0 (22.4)</P>
</TD>
<TD>
<P>T1 +0.08 (0.63)<BR/>T2 +0.13 (0.62)<BR/>C +0.17 (0.70)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>?</P>
</TD>
</TR>
<TR>
<TD>
<P>Blood pressure systolic change [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 -2.1 (12.3)<BR/>T2 -0.4 (11.8)<BR/>C -0.3 (10.1)</P>
</TD>
<TD>
<P>T1 -1.0 (12.5)<BR/>T2 -0.9 (12.5)<BR/>C -0.3 (12.3)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>T1 -0.8 (12.8)<BR/>T2 -0.4 (12.9)<BR/>C +1.6 (13.2)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Blood pressure diastolic change [mean,SD] (T1/ T2 / C1 / total)</P>
</TD>
<TD>
<P>T1 -1.7 (8.5)<BR/>T2 -0.1 (8.3)<BR/>C -0.2 (7.4)</P>
</TD>
<TD>
<P>T1 -0.9 (8.7)<BR/>T2 -0.8 (8.8)<BR/>C -0.1 (8.5)</P>
</TD>
<TD>
<P>?</P>
</TD>
<TD>
<P>T1 -1.9 (8.2)<BR/>T2 -0.4 (8.5)<BR/>C -0.7 (8.4)<BR/>
</P>
</TD>
</TR>
<TR>
<TD>
<P>Notes</P>
</TD>
<TD>
<P>results by last observation carried forward</P>
</TD>
<TD>
<P>results by last observation carried forward</P>
</TD>
<TD>
<P>results by last observation carried forward<BR/>results published as placebo subtract changes from baseline for 1 year, this results were obtained from results published in American Hearth Association 2004 Scientific Sessions - http://www.medscape.com/viewarticle/493901</P>
</TD>
<TD>
<P>results by last observation carried forward</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Symbols: unclear=?</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
<TR>
<TD>
<P>Abbreviations: T=treatment; C=control</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>